

DN	98339375	Published ID: 9676753	TI	Flow cytometry in the preclinical development of biopharmaceuticals.
AU		Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.	AU	Gossett K.A.; Narayanan P.K.; Williams D.M.; Gore E.R.; Herzky D.J.; Hart T.K.; Sellers T.S.
AU		Yocum D.E.; Solinger A.M.; Tesser J.; Gluck O.; Cornett M.; O'Sullivan F.; Nordenson K.; Dahlil B.; Shen C.D.; Lippini J.	CS	SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA. kent.gossett@gbphrd.com
SO		Department of Medicine, Arizona Health Sciences Center, Tucson 85724, USA.	SO	TOXICOLOGIC PATHOLOGY, (1999). Vol. 27, No. 1, pp. 32-7.
SO		Journal code: TOX. ISSN: 0192-6233.	DR	Journal, Article; (JOURNAL ARTICLE)
CY		Journal code: 7501984. ISSN: 0315-162X.		General Review; (REVIEW)
DT		(CLINICAL TRIAL)		(REVIEW, TUTORIAL)
		(CLINICAL TRIAL, PHASE I)		MED; J; Priority Journals
LA		JOURNAL; Article; (JOURNAL ARTICLE)		English
LA		(MULTICENTER STUDY)		OS
FS		English		MEDLINE 98294090
FS		Priority Journals; AIDS		EM 199908
EM	199809	199809	FS	ANSWER 5 OF 63 MEDLINE
ED		Entered STN: 1998008	FS	ANSWER 8 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
TI		Last Updated on STN: 19981008	FS	200127460 EMBASE
Entered Medline: 19980929		Entered Medline: 19980929	TI	The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma.
AU		ANSWER 5 OF 63 MEDLINE	AU	Kon O.M.; Sihra B.S.; Loh L.C.; Barkans J.; Compton C.H.; Barnes N.C.; Larche M.; Kay A.B.
AN	97335220	MEDLINE	CS	A.B. Kay, Dept. of Allergy/Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, United Kingdom
DN	97335220	PubMed ID: 9191886	SO	European Respiratory Journal, (2001) 18/1 (45-52).
TI		A primatized Mab to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a Mab (IMPC-CB9.1) to human CD4.	RefS:	27
AU		Anderson D.; Chambers K.; Hanna N.; Leonard J.; Reff M.; Newman R.; Baldoni J.; Dunleavy D.; Reddy M.; Sweet R.; Truneh A.	ISSN:	0903-1936 CODEN: ERJ0E1
CS		IMPC Pharmaceuticals Corporation, San Diego, California 92121, USA.	DR	Switzerland
SO		CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, (1997 Jul) 84 (1) 73-84.	FS	Journal, Article
CY		Journal code: 0356637. ISSN: 0090-1229.	015	Chest Diseases, Thoracic Surgery and Tuberculosis
United States		United States	026	Immunology, Serology and Transplantation
DT		Journal; Article; (JOURNAL ARTICLE)	030	Pharmacology
LA		English	037	Drug Literature Index
LA		Priority Journals	SL	English
FS		Priority Journals		English
EM	199707	Entered STN: 19970721	FS	ANSWER 9 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ED		Last Updated on STN: 19990206	FS	200037445 EMBASE
Entered Medline: 19970708		Entered Medline: 19970708	TI	Chimeric human-simian anti-CD4 antibodies form crystalline high symmetry particles.
AU		ANSWER 6 OF 63 MEDLINE	AU	Kuznetsov Yu.G.; Day J.; Newman R.; McPerson A.
AN	97041345	MEDLINE	CS	Yu.G. Kuznetsov, Department of Biochemistry, University of California, Irvine, CA 92697-3900, United States
DN	97041345	PubMed ID: 8886616	SO	Journal of Structural Biology, (2000) 131/2 (108-115).
TI		Disposition of metabolically radiolabeled CB9.1--a macaque-human chimeric anti-human CD4 monoclonal antibody--in transgenic mice bearing human CD4.	RefS:	22
AU		Davis C.B.; Garver E.M.; Kwok D.C.; Urbanski J.J.	ISSN:	1047-8477 CODEN: JSBTEM
CS		Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA.	DR	United States
SO		DRUG METABOLISM AND DISPOSITION, (1996 Sep) 24 (9) 1032-7.	FS	Journal, Article
CY		Journal code: 9421550. ISSN: 0090-9556.	026	Immunology, Serology and Transplantation
United States		United States	037	Drug Literature Index
DT		Journal; Article; (JOURNAL ARTICLE)	SL	English
LA		English		English
LA		Priority Journals		English
FS		Priority Journals		English
EM	199702	Entered STN: 19970227	FS	ANSWER 10 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ED		Last Updated on STN: 19970227	TI	Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: Cd4+ T-cell depletion is not required.
Entered Medline: 19970212		Entered Medline: 19970212	AU	Podolny P.L.; Webb E.F.; Reddy M.; Truneh A.; Griswold D.E.
AU		ANSWER 7 OF 63 CANCERLIT	CS	King of Prussia, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406, United States
AN	199294990	CANCERLIT	RefS:	44
DN	99294090		ISSN:	0019-2805 CODEN: IMMUM
CY		United Kingdom		

DT Journal; Article
 FS Immunology, Serology and Transplantation
 026
 037 Drug Literature Index
 LA English
 SL English

L1 ANSWER 11 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 1998288616 EMBASE
 TI Randomised, dose-ranging, placebo-controlled study of chimeric antibody to
 AU Kon O.M.; Sinha B.S.; Compton C.H.; Leonard T.B.; Kay A.B.; Barnes N.C.
 CS Dr. N.C. Barnes, Department of Respiratory Medicine, London Chest
 SO Hospital, London E2 9JX, United Kingdom
 Lancet, (3 Oct 1998) 352/9134 (1109-1113).
 Refs: 2,4
 ISSN: 0140-6736 CODEN: LANCAO

CY United Kingdom
 DT Journal; Article
 015 Chest Diseases, Thoracic Surgery and Tuberculosis
 026 Immunology, Serology and Transplantation
 030 Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LA English
 SL English

L1 ANSWER 12 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 1998229884 EMBASE
 TI Subcutaneous bioavailability of a PRIMATIZED™ IgG1 anti-human CD4 monoclonal antibody is dose dependent in transgenic mice bearing human CD4.
 AU Davis C.B.; Bugelski P.J.
 CS Dr. C.B. Davis, SmithKline Beecham Pharmaceuticals, Drug Metabolism and Pharmacokinetics, Mail Code UW2720, 709 Swedeland Road, King of Prussia, PA 19406, United States
 SO Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents, (1998) 5/2 (95-100).
 Refs: 12
 ISSN: 1071-7544 CODEN: DDELEB

CY United States
 DT Journal; Article
 026 Immunology, Serology and Transplantation
 030 Pharmacology
 036 Health Policy, Economics and Management
 037 Drug Literature Index
 039 Pharmacy
 LA English
 SL English

L1 ANSWER 13 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 1998229162 EMBASE
 TI Clinical and immunologic effects of a PRIMATIZED™ anti-CD4 monoclonal antibody in active rheumatoid arthritis: Results of a phase I, single dose, dose escalating trial.
 AU Yocum D.E.; Solinger A.M.; Teiser J.; Gluck O.; Cornett M.; O'Sullivan F.; Nordenson K.; Dalaire B.; Siem C.D.; Lipani J.
 CS Dr. D.E. Yocum, ARSC, 1501 N. Campbell, Tucson, AZ 85724, United States
 SO Journal of Rheumatology, (1998) 25/7 (1257-1262).
 Refs: 32
 ISSN: 0315-162X CODEN: JRHUA

CY Canada
 DT Journal; Article
 031 Arthritis and Rheumatism
 037 Drug Literature Index

L1 ANSWER 14 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 1998136858 EMBASE
 TI Biological agents in rheumatoid arthritis: Which ones could be used in combination?
 AU Lorenz H.-M.; Kalden J.R.
 CS Dr. H.-M. Lorenz, Department of Medicine III, Inst. Clinical Immunol./Rheumatology, University of Erlangen-Nürnberg, Erlangen, Germany. Hannes.Lorenz@med3.med.uni-erlangen.de
 SO BioDrugs, (1998) 9/4 (303-324).
 Refs: 130
 ISSN: 1173-8804 CODEN: BIDRF4

CY New Zealand
 DT Journal; General Review
 026 Immunology, Serology and Transplantation
 030 Pharmacology
 031 Arthritis and Rheumatism
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LA English
 SL English

L1 ANSWER 15 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 91209580 EMBASE
 TI A primatized Mab to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: In vitro and in vivo characterization of a Mab (IDSC-CB9.1) to human CD4.
 AU Anderson D.; Chambers K.; Hanna N.; Leonard J.; Reff M.; Newman R.; Baldoni J.; Dunleavy D.; Reddy M.; Sweet R.; Truneh A.
 CS IDSC Pharmaceuticals Corporation, 11011 Torreyana Road, San Diego, CA 92121, United States
 SO Clinical Immunology and Immunopathology, (1997) 84/1 (73-84).
 Refs: 41
 ISSN: 0890-1229 CODEN: CLIMAT

CY United States
 DT Journal; Article
 026 Immunology, Serology and Transplantation
 LA English
 SL English

L1 ANSWER 16 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 96288995 EMBASE
 TI Disposition of metabolically radiolabeled CB9.1 - A macaque-human chimeric anti-human CD4 monoclonal antibody-in transgenic mice bearing human CD4.
 AU Davis C.B.; Garver E.M.; Kwok D.C.; Urbanski J.J.
 CS SmithKline Beecham Pharmaceuticals, Drug Metabolism and Pharmacokinetics, Mail Code UW2730, 709 Swedeland Road, King of Prussia, PA 19406, United States
 SO Drug Metabolism and Disposition, (1996) 24/9 (1032-1037).
 ISSN: 0890-5556 CODEN: DMDSAI

CY United States
 DT Journal; Article
 026 Immunology, Serology and Transplantation
 030 Pharmacology
 037 Drug Literature Index
 LA English
 SL English

LI ANSWER 17 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001:410273 BIOSIS
 DN PREV199800100410273
 TT The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma.
 AU Kon, O. M.; Sihra, B. S.; Ioh, L. C.; Barkans, J.; Compton, C. H.; Barnes, N. C.; Larche, M.; Kay, A. B. (1)
 CS (1) Dept of Allergy and Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY UK
 SO European Respiratory Journal, (July, 2001) Vol. 18, No. 1, pp. 45-52.
 PRNT. ISSN: 0903-1936.

DT Article
 LA English

LI ANSWER 18 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1999:146171 BIOSIS
 DN PREV199800146171
 TI Flow cytometry in the preclinical development of biopharmaceuticals.
 AU Gossett, Kent A. (1); Narayanan, Padma K.; Williams, Donna M.; Gore, Elizabeth R.; Hezryk, Donata J.; Hart, Timothy K.; Sellers, Teresa S.
 CS (1) SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406 USA
 SO Toxicologic Pathology, (Jan.-Feb., 1999) Vol. 27, No. 1, pp. 32-37.
 DT Article
 LA English

LI ANSWER 19 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:520004 BIOSIS
 DN PREV199800520004
 TI Tight ligand binding affinities determined from thermodynamic linkage to temperature by titration calorimetry.
 AU Doyle, Michael L. (1); Hendley, Preston C.
 CS (1) Dep. Structural Biology, SmithKline Beecham Pharmaceutical, King of Prussia, PA 19406 USA
 SO Ackers, G. K. [Editor]; Johnson, M. L. [Editor]. Methods in Enzymology, (1998) Vol. 295, pp. 88-99. Methods in Enzymology; Energetics of biological macromolecules, Part B.
 Publisher: Academic Press, Inc. 1250 Sixth Ave., San Diego, California 92101, USA.
 ISSN: 0076-6879. ISBN: 0-12-182196-X.

DT Book
 LA English

LI ANSWER 20 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:405409 BIOSIS
 DN PREV1998000405409
 TI Randomized, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma.
 AU Kon, Om M.; Shira, Bhupinder S.; Compton, Christopher H.; Leonard, Thomas B.; Kay, A. Barry; Barnes, Neil C. (1)
 CS (1) Dep. Respiratory Med., London Chest Hosp., London E2 9JX UK
 SO Lancet (North American Edition), (Oct. 3, 1998) Vol. 352, No. 9134, pp. 1109-1113.
 ISSN: 0009-5355.

DT Article
 LA English

LI ANSWER 21 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:368117 BIOSIS
 DN PREV199800368117

TI Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: Results of a phase I, single dose, dose escalating trial.
 AU Yocum, David E. (1); Solinger, Alan M.; Tesser, John; Gluck, Oscar; Cornet, Michelle; O'Sullivan, Frank; Nordensson, Kathy; Dallaire, Brian; Shen, C. David; Lian, John
 CS (1) Room 6409, 1501 N. Campbell, P.O. Box 245029, Tucson, AZ 85724 USA
 SO Journal of Rheumatology, (July, 1998) Vol. 25, No. 7, pp. 1257-1262.
 ISSN: 0315-162X.

DT Article
 LA English

LI ANSWER 22 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:18808 BIOSIS
 DN PREV199800158088
 TI Treatment of rheumatoid arthritis with a primatized anti-CD4 monoclonal antibody, SB-210396 (IDEC-C89.1). Results of an open label extension study in patients responding to induction therapy.
 AU Teiser, John R. P. (1); Wiesenhutter, Craig; Levy, Robert; Schiff, Michael; Lipani, John; Solinger, Alan; MacDonald, Brian; Elliott, Michael; Singh, Krishan
 CS (1) Phoenix, AZ 85015 USA
 SO Arthritis & Rheumatism, (Sept., 1997) Vol. 40, No. 9 SUPPL., pp. S224. Meeting Info.: 61st National Scientific Meeting of the American College of Rheumatology and the 32nd National Scientific Meeting of the Association of Rheumatology Health Professionals Washington, DC, USA November 8-12, 1997. Association of Rheumatology Health Professionals ISSN: 0004-3591.

DT Conference
 LA English

LI ANSWER 23 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:57892 BIOSIS
 DN PREV199800157892
 TI Treatment of rheumatoid arthritis with a primatized anti-CD4 monoclonal antibody, SB-210396 (IDEC-C89.1): Responsiveness correlates with duration of monoclonal antibody coating. CD4 receptor modulation and decrease in number of activated lymphocyte subpopulations.
 AU Truneh, Ale; Macdonald, Brian (1); Elliott, Michael (1); Singh, Krishan (1); Solinger, Alan
 CS (1) SmithKline Beecham, Collegeville, PA 19426 USA
 SO Arthritis & Rheumatism, (Sept., 1997) Vol. 40, No. 9 SUPPL., pp. S191. Meeting Info.: 61st National Scientific Meeting of the American College of Rheumatology and the 32nd National Scientific Meeting of the Association of Rheumatology Health Professionals Washington, DC, USA November 8-12, 1997. Association of Rheumatology Health Professionals ISSN: 0004-3591.

DT Conference
 LA English

LI ANSWER 24 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:153517 BIOSIS
 DN PREV199800153517
 TI In vitro inhibitory effects of a PRIMATIZED anti-CD4 monoclonal antibody, SB210396 (IDEC-C89.1), on allergen specific T-cell proliferation and cytokine production in atopic asthmatics.
 AU Ioh, L. C. (1); Kon, O. M. (1); Sihra, B. S. (1); Till, S. J. (1); Barkans, J. (1); Compton, C. H.; Barnes, N. C.; Kay, A. B. (1)
 CS (1) Natl. Heart Lung Inst., SmithKline Beecham Pharmaceuticals, London UK
 SO Journal of Allergy and Clinical Immunology, (Jan., 1998) Vol. 101, No. 1 PART 2, pp. S11. Meeting Info.: 54th Annual Meeting of the American Academy of Allergy, Asthma and Immunology Washington, DC, USA March 13-18, 1998 American Academy of Allergy, Asthma, and Immunology

. ISSN: 0091-6749.
 DT Conference
 LA English

L1 ANSWER 25 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:153748 BIOSIS
 PREV199800153748
 SO In vivo effects of a PRIMATIZED anti-CD4 monoclonal antibody, SB210396
 TI (IDEC CE9.1), on CD4+ T lymphocytes in chronic severe asthma.
 AU Kon, O. M. (1); Sirha, B. S. (1); Barkans, J. (1); Compton, C. H.; Barnes, N. C.; Kay, A. B. (1)
 CS (1) Natl. Heart Lung Inst., SmithKline Beecham Pharmaceuticals, London UK
 SO Journal of Allergy and Clinical Immunology, (Jan., 1998) Vol. 101, No. 1.
 PART 2, pp. 59.
 Meeting Info.: 54th Annual Meeting of the American Academy of Allergy, Asthma and Immunology Washington, DC, USA March 13-18, 1998 American Academy of Allergy, Asthma, and Immunology
 ISSN: 0091-6749.
 DT Conference
 LA English

L1 ANSWER 26 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:103440 BIOSIS
 DN PREV199800103440
 TI Pharmacokinetics and pharmacodynamics of SB 210396 (IDEC CE9.1), a primatized anti-human CD4 monoclonal antibody, in patients with stable severe asthma.
 AU Zia-Hussaini, P. (1); Citterone, D. R. (1); Davis, C. B. (1); Sirha, B. S.; Compton, C. H. (1); Kon, O. M.; Kay, A. B.; Barnes, N. C. (1); SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406 USA
 CS Pharmaceutical Research (New York), (Nov., 1997) Vol. 14, No. 11 SUPPL., pp. S509.
 PP. S509.
 Meeting Info.: Annual Meeting of the American Association of Pharmaceutical Scientists Boston, Massachusetts, USA November 2-6, 1997
 American Association of Pharmaceutical Scientists
 ISSN: 0724-8741.
 DT Conference
 LA English

L1 ANSWER 27 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:104346 BIOSIS
 DN PREV199800104346
 TI Non-linear pharmacokinetics of SB 210396 (IDEC CE9.1), a primatized anti-human CD4 monoclonal antibody in transgenic mice bearing human CD4.
 AU Davis, C. B.; Steiman, G. J.; Urbanski, J. J.
 CS Drug Metabolism Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406 USA
 SO Pharmaceutical Research (New York), (Nov., 1997) Vol. 14, No. 11 SUPPL., pp. S516.
 PP. S516.
 Meeting Info.: Annual Meeting of the American Association of Pharmaceutical Scientists Boston, Massachusetts, USA November 2-6, 1997
 American Association of Pharmaceutical Scientists
 ISSN: 0724-8741.
 DT Conference
 LA English

L1 ANSWER 28 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1997:321016 BIOSIS
 DN PREV199709611504
 TI A primatized Mab to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: In vitro and in vivo characterization of a Mab (IDEC-CE9.1) to human CD4,
 DT Conference
 LA English

L1 ANSWER 29 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:514251 BIOSIS
 DN PREV199800514251
 TI Disposition of metabolically radiolabeled CE9.1-A macaque-human chimeric anti-human CD4 monoclonal antibody-in transgenic mice bearing human CD4.
 AU Davis, Charles B. (1); Garver, Eric M.; Kwok, Deborah C.; Urbanski, James (1) SmithKline Beecham Pharm., Drug Metabolism Pharm., P.O. Box 1539, Mail Code UN2730, 709 Swedenland Road, King of Prussia, PA 19406 USA
 SO Drug Metabolism and Disposition, (1996) Vol. 24, No. 9, pp. 1032-1037.
 DT Article
 LA English

L1 ANSWER 30 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:01921 BIOSIS
 DN PREV199609224277
 TI Pharmacology and safety of anti-CD4 antibody IDEC-CE9.1 in HuCdk4 transgenic mice.
 AU Bugielski, Peter (1); Giswold, Don; Badger, Alison; Rehm, Sabine; Truneh, Almased; Herzyk, Danuta
 CS (1) SmithKline Beecham Pharm., Philadelphia, PA USA
 SO Arthritis & Rheumatism, (1995) Vol. 39, No. 9 SUPPL., pp. S247.
 Meeting Info.: 50th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals Orlando, Florida, USA October 18-22, 1996
 ISSN: 0044-3991.
 DT Conference
 LA English

L1 ANSWER 31 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:309276 BIOSIS
 DN PREV199609031632
 TI Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, non-depleting Primatized anti-CD4 monoclonal antibody in rheumatoid arthritis (RA).
 AU Solinger, A. (1); Paxton, H.; Key, K.; Yocum, D.
 CS (1) IDEC Pharmaceuticals, San Diego, CA 92121 USA
 SO FASEB Journal, (1996) Vol. 10, No. 6, pp. A1314.
 Meeting Info.: Joint Meeting of the American Society for Biochemistry and Molecular Biology, the American Society for Investigative Pathology and the American Association of Immunologists New Orleans, Louisiana, USA June 2-6, 1996
 ISSN: 0892-6638.
 DT Conference
 LA English

L1 ANSWER 32 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:50703 BIOSIS
 DN PREV199509835003
 TI Results of a multi-dose protocol 7002 using an immunomodulating, non-depleting PRIMATIZED anti-CD4 monoclonal antibody in rheumatoid arthritis (RA).

AU Kaine, Jeffrey (1); Solinger, Alan; Yocum, David; Lipani, John; Klas, Pam;
 Tesser, John; Wiesenhutter, Craig; O'Sullivan, Frank; Shuman, Sherry;
 Rugby, William
 CS (1) Sarasota Arthritis Center, Sarasota, FL 34239 USA
 SO Arthritis & Rheumatism, (1995) Vol. 38, No. 9 SUPPL., pp. S185.
 Meeting Info.: 59th National Scientific Meeting of the American College of
 Rheumatology and the 30th National Scientific Meeting of the Association
 of Rheumatology Health Professionals San Francisco, California, USA
 October 21-26, 1995
 ISSN: 0004-3591.
 DT Conference
 LA English
 L1 ANSWER 33 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:281708 BIOSIS
 DN PREV199558302008
 TI Clinical and immunopharmacologic effects of primatized-TM IDEC-CE9
 (1) an anti-CD4 monoclonal antibody in a phase I trial in active
 rheumatoid arthritis.
 AU Yocum, D. E. (1); Solinger, A. M.; Lipani, J.; Tesser, J.; Gluck, O.;
 Sullivan, F. O.; Mararesu, M.; Cornett, M.; Wei, K.; Nordenson, K.
 CS (1) Univ. Arizona, Tucson, AZ USA
 SO Journal of Investigative Medicine, (1995) Vol. 43, No. SUPPL. 2, pp. 253A.
 Meeting Info.: Clinical Research Meeting San Diego, California, USA May
 5-8, 1995
 DT Conference
 LA English
 L1 ANSWER 34 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:4701 BIOSIS
 DN PREV199598019001
 TI Clinical activity in an early phase I trial of primatized IDEC-CE9
 (1) - an anti-CD4 monoclonal antibody in RA.
 AU Solinger, A. M. (1); Yocum, D. E.; Tesser, J.; Gluck, O.; O'Sullivan, F.;
 Henkel, C. (1); Cornett, M.; Lipani, J. 9121 USA
 CS (1) IDEC Pharm. Corp., San Diego, CA 9121 USA
 SO Arthritis & Rheumatism, (1994) Vol. 37, No. 9 SUPPL., pp. S337.
 Meeting Info.: 58th National Scientific Meeting of the American College of
 Rheumatology and the 29th National Scientific Meeting of the Association
 of Rheumatology Health Professionals Minneapolis, Minnesota, USA October
 23-27, 1994
 ISSN: 0004-3591.
 DT Conference
 LA English
 L1 ANSWER 34 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:4701 BIOSIS
 DN PREV199598019001
 TI Clinical activity in an early phase I trial of primatized IDEC-CE9
 (1) - an anti-CD4 monoclonal antibody in RA.
 AU Solinger, A. M. (1); Yocum, D. E.; Tesser, J.; Gluck, O.; O'Sullivan, F.;
 Henkel, C. (1); Cornett, M.; Lipani, J. 9121 USA
 CS (1) IDEC Pharm. Corp., San Diego, CA 9121 USA
 SO Arthritis & Rheumatism, (1994) Vol. 37, No. 9 SUPPL., pp. S337.
 Meeting Info.: 58th National Scientific Meeting of the American College of
 Rheumatology and the 29th National Scientific Meeting of the Association
 of Rheumatology Health Professionals Minneapolis, Minnesota, USA October
 23-27, 1994
 ISSN: 0004-3591.
 DT Conference
 LA English
 L1 ANSWER 35 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:4705 BIOSIS
 DN PREV199598018995
 TI Immunomodulatory effect of primatized-TM IDEC-CE9, 1 an
 ANTI-CD4 monoclonal antibody, in RA.
 AU Yocum, D. E. (1); Nordenson, K. (1); Solinger, A. M.
 CS (1) Univ. Arizona, Tucson, AZ 85724 USA
 SO Arthritis & Rheumatism, (1994) Vol. 37, No. 9 SUPPL., pp. S336.
 Meeting Info.: 58th National Scientific Meeting of the American College of
 Rheumatology and the 29th National Scientific Meeting of the Association
 of Rheumatology Health Professionals Minneapolis, Minnesota, USA October
 23-27, 1994
 ISSN: 0004-3591.
 DT Conference
 LA English

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE IN THE RE FORMAT
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L1 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1995:477381 CAPLUS
 DN 131:138677
 TI Clenoliximab SmithKline Beecham
 AU Norman, Peter
 CS Current Opinion in Anti-Inflammatory and Immunomodulatory Investigations, 1
 SO Drugs (1999), 1(2), 165-170
 CODEN: COAIFI; ISSN: 1464-8474
 PB Current Drugs Ltd.
 DT Journal: General Review
 LA English
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L1 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:130154 CAPLUS
 DN 130:346646
 TI Flow cytometry in the preclinical development of biopharmaceuticals
 AU Gossett, Kent A.; Narayan, Padma K.; Williams, Donna M.; Gore, Elizabeth
 R.; Herzyk, Donata J.; Hart, Timothy K.; Sellers, Teresa S.
 CS SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA
 SO Toxicologic Pathology (1999), 27(1), 32-37
 CODEN: TOPADD; ISSN: 0192-6233
 PB Society of Toxicologic Pathologists
 DT Journal: General Review
 LA English
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE IN THE RE FORMAT
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L1 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:691752 CAPLUS
 DN 130:9193
 TI Randomized, dose-ranging, placebo-controlled study of chimeric antibody to
 CD4 (eliximab) in chronic severe asthma
 AU Kon, Onn M.; Sihra, Bhupinder S.; Compton, Christopher H.; Leonard, Thomas
 B.; Kay, A. Barry; Barnes, Neil C.
 CS London Chest Hospital, London, E2 9AX, UK
 SO Lancet (1998), 352 (9134), 109-113
 CODEN: LANCAC; ISSN: 0140-6736
 PB Lancet Ltd.
 DT Journal
 LA English
 RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L1 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:47014 CAPLUS
 DN 129:229418
 TI Clinical and immunologic effects of a Primatized anti-CD4 monoclonal

antibody in active rheumatoid arthritis: results of a Phase I, single dose, dose escalating trial

AU Yocum, David E.; Solinger, Alan M.; Teeser, John; Gluck, Oscar; Cornett, Michelle; O'sullivan, Frank; Nordensson, Kathy; Ballaire, Brian; Shen, C. David; Lipani, John

CS Department of Medicine, Arizona Health Sciences Center (AHSC), Tucson, AZ, 85724, USA

SO Journal of Rheumatology (1998), 25(7), 1257-1262

PB CODEN: JRHUG9; ISSN: 0315-162X

Journal of Rheumatology Publishing Co. Ltd.

DT English

LA

L1 ANSWER 41 OF 63 CAPLUS COPYRIGHT 2002 ACS

AN 1998:426327 CAPLUS

DN 129:156339

TI Biological agents in rheumatoid arthritis: which ones could be used in combination?

AU Lorenz, Hans-Martin; Kalden, Joachim R.

CS Department of Medicine III, Institute for Clinical Immunology and Rheumatology, University of Erlangen-Nuremberg, Erlangen, Germany

SO BiDrugs (1998), 9(4), 303-324

COEN: BIDBF4; ISSN: 1173-8804

FB Adis International Ltd

DT Journal; General Review

LA English

L1 ANSWER 42 OF 63 CAPLUS COPYRIGHT 2002 ACS

AN 1998:17658 CAPLUS

DN 129:153105

TI Subcutaneous bioavailability of a PRIMATIZED IgG1 anti-human CD4 monoclonal antibody is dose dependent in transgenic mice bearing human CD4

AU Davis, Charles B.; Bugelski, Peter J.

CS Drug Metabolism Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA

SO Drug Delivery (1998), 5(2), 95-100

COEN: DDBLEB; ISSN: 1071-7544

FB Taylor & Francis

DT Journal

LA English

L1 ANSWER 43 OF 63 CAPLUS COPYRIGHT 2002 ACS

AN 1998:123645 CAPLUS

DN 128:191337

TI The therapeutic potential of a primatized nondepleting anti-CD4 (IDECKB9.1) monoclonal antibody in rheumatoid arthritis

AU Solinger, Alan M.; Irunen, Allemeged; Lipani, John A.; Newman, Roland A.

CS IDEC Pharmaceutical Corporation, San Diego, CA, USA

SO Antibody Therapeutics (1997), 3(1-3):3

Adair, John R. Publisher: CRC, Boca Raton, Fla.

COEN: 65RLAP

DT Conference; General Review

LA English

L1 ANSWER 44 OF 63 CAPLUS COPYRIGHT 2002 ACS

AN 1997:422612 CAPLUS

DN 127:120496

TI A Primatized Mab to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a Mab (IDECKB9.1) to human CD4

AU Anderson, Darrell; Chambers, Karen; Leonard, John; Reff, Mitchell; Newman, Roland; Baldoni, John; Dunleavy, Donna; Reddy, Manjula; Sweet, Raymond; Truneh, Almased

CS IDEC Pharmaceuticals Corporation, San Diego, CA, 92121, USA

SO Clinical Immunology and Immunopathology (1997), 84(1), 73-84

PB CODEN: CLIAT; ISSN: 0090-1229

DT Academic Journal

LA English

L1 ANSWER 45 OF 63 CAPLUS COPYRIGHT 2002 ACS

AN 1997:290112 CAPLUS

DN 126:1263167

TI Recombinant anti-CD4 antibodies for human therapy

IN Hanna, Nabil; Newman, Roland A.; Roff, Mitchell E.

PA Idec Pharmaceuticals Corporation, USA

SO PCT Int. Appl., 154 pp.

COEN: PIXXD2

DT Patent

LA English

L1 ANSWER 46 OF 63 CAPLUS COPYRIGHT 2002 ACS

AN 1997:290102 CAPLUS

DN 126:1263168

TI Recombinant anti-CD4 antibodies for human therapy

IN Hanna, Nabil; Newman, Roland A.; Roff, Mitchell E.

PA Idec Pharmaceuticals Corporation, USA

SO PCT Int. Appl., 154 pp.

COEN: PIXXD2

DT Patent

LA English

L1 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2002 ACS

AN 1996:589160 CAPLUS

DN 125:245208

TI Disposition of metabolically radiolabeled CB9.1. - A macaque-human chimeric anti-human CD4 monoclonal antibody-in transgenic mice bearing human CD4

AU Davis, Charles B.; Garver, Eric M.; Kwok, Deborah C.; Urbanski, James J.
CS Drug Metab. Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King
Prussia, PA, 19406, USA
SO Drug Metab. Dispos. (1996), 24(9), 1032-1037
CODEN: DMDSAI; **ISSN:** 0090-9556
DR Journal
LA English
L1 ANSWER 48 OF 63 USPATFULL
AN 2002:442429 USPATFULL
 Conjugates of dithiocarbamates with pharmacologically active agents and
 uses therefor
IN Lai, Ching-San, Encinitas, CA, United States
 Wang, Tingmin, San Marcos, CA, United States
PA Medina, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6407135 B1 20020618
AT US 1999-453608 19991203 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US10295, filed on 19 May 1998
 Continuation of Ser. No. US 1997-869158, filed on 4 Jun 1997, now
 patented, Pat. No. US 5916910
DT Utility
ES GRANTED
LN.CNT 2157
INCL INCLM: 514/423.000
 INCLS: 511/002.000; 514/514.000; 530/402.000; 548/565.000; 548/573.000
NCL NCLM: 514/423.000
 NCLS: 514/002.000; 514/514.000; 530/402.000; 548/565.000; 548/573.000
IC [7]
ICM: C07D207-04
AN ICS: C07D207-04; A61K031-27; A61K031-40
EXF 530/402; 530/300; 530/356; 514/8-25; 514/2; 514/423; 514/514; 548/565;
 548/573
L1 ANSWER 49 OF 63 USPATFULL
AN 2002:8531 USPATFULL
 POLYDITHIOCARBAMATE-CONTAINING NON-TARGETING MACROMOLECULES AND THE USE
 THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
IN LAT, CHING-SAN, ENCINITAS, CA, UNITED STATES
PI US 1999-405573 A1 20020418
AI US 1999-409645 A1 19991001 (9)
RLI Continuation-in-part of Ser. No. US 1997-899087, filed on 23 Jul 1997,
 ABANDONED
PRAI US 1996-25867P 19960910 (60)
DT Utility
FS APPLICATION
LN.CNT 1763
INCL INCLM: 514/006.000
 INCLS: 514/044.000; 514/054.000; 514/476.000; 514/483.000;
NCL NCLM: 514/006.000
 NCLS: 514/044.000; 514/405.000; 514/455.000; 536/022.100; 536/123.100
IC [7]
ICM: A61K038-16
IC ICS: A61K031-415; C07K021-00; A61K031-715; A01N043-04; A61K031-70;
 C07H001-00; C08H001-00; C07K017-00; A01N043-56; A61K031-27; A01N047-10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L1 ANSWER 50 OF 63 USPATFULL
AN 2002:7987 USPATFULL
 Treatment of B cell malignancies using combination of B cell depleting
 antibody and immune modulating antibody related applications
IN Hanne, Nabil, Rancho Santa Fe, CA, UNITED STATES
 Hariharan, Kandasamy, San Diego, CA, UNITED STATES

PI US 2002028178
AI US 22001-855717
PRAI US 2000-217706P
FS DT
DT APPLICATION
LN.CNT 3047
INCL INCLM: 424/001.490
 INCLS: 424/143.100
NCL NCIM: 424/001.490
 NCIS: 424/143.100
IC ICM: 424/143.100
 ICS: A61K039-395
 ICM: A61K051-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L1 ANSWER 51 OF 63 USPATFULL
AN 2002:12028 USPATFULL
 Treatment of cell malignancies using combination of B cell depleting
 antibody and immune modulating antibody related applications
IN Hanna, Nabil, Rancho Santa Fe, CA, UNITED STATES
 Hariharan, Kandasamy, San Diego, CA, UNITED STATES
PI IDEC Pharmaceuticals Corporation (U.S. corporation)
AI US 2002006404 A1 20020117
RLI US 2001-772938 A1 20010131 (9)
 Continuation-in-part of Ser. No. US 1999-435992, filed on 8 Nov 1999,
 PENDING
DT Utility
FS APPLICATION
LN.CNT 2147
INCL INCLM: 424/142.100
 INCLS: 424/155.100
NCL NCIM: 424/142.100
 NCIS: 424/155.100
IC [7]
AN ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L1 ANSWER 52 OF 63 USPATFULL
AN 2001:231946 USPATFULL
IN TI Method of treating immune cell mediated systemic diseases
 Bugeiski, Peter John, Drexel Hill, PA, United States
 Davis, Charles Baldwin, Devon, PA, United States
 McDonald, Brian Richard, Valley Forge, PA, United States
PA SmithKline Beecham Corporation (U.S. corporation)
PI US 2001056066 A1 20011227
AI US 2001-90536 A1 20010713 (9)
RLI Continuation of Ser. No. US 1999-220119, filed on 26 May 1999, ABANDONED
 UNKNOWN
PRAI A 371 of International Ser. No. WO 1997-US12600, filed on 25 Jul 1997,
 US 1996-22472P 19960726 (60)
DT Utility
FS APPLICATION
LN.CNT 1105
INCL INCLM: 514/008.000
 INCLS: 424/131.100
NCL NCIM: 514/008.000
 NCIS: 424/131.100
IC [7]
ICM: A61K038-16
 ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L1 ANSWER 53 OF 63 USPATFULL
AN 2001:202682 USPATFULL

TI Therapeutic methods employing disulfide derivatives of dithiocarbonates and compositions useful therefor
 IN Lai, Ching-San, Encinitas, CA, United States
 PA Vassilev, Vassil, San Diego, CA, United States
 PA Mediob, Inc., San Diego, CA, United States (U.S. corporation)
 PT US 6316502, B1 2001113
 AT US 20005566 2000505 (9)
 RLI Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, now patented, Pat. No. US 6093743
 DT Utility
 FS GRANTED
 LN,CNT 2591
 INCL: 514/599.000
 INCLS: 514/707.000; 514/825.000; 514/838.000; 514/851.000; 514/861.000;
 514/866.000; 514/885.000; 514/903.000; 514/912.000; 514/925.000
 NCL: 514/599.000
 NCIS: 514/707.000; 514/825.000; 514/838.000; 514/851.000; 514/861.000;
 514/866.000; 514/885.000; 514/903.000; 514/912.000; 514/925.000
 IC [7] ICM: A01N037-18
 EXF 514/599; 514/707; 514/825; 514/838; 514/851; 514/861; 514/863;
 514/866; 514/903; 514/932; 514/925
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 54 OF 63 USPATFULL
 AN 2001:186209 USPATFULL
 TI Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
 IN Barber-Guillem, Emilio, Powell, OH, United States
 PI US 2001033839, A1 20011025
 AI US 2001-835759, A1 20010416 (9)
 RLI Continuation-in-part of Ser. No. US 1999-411116, filed on 4 Oct 1999,
 UNKNOWN
 DT Utility
 FS APPLICATION
 LN,CNT 2272
 INCL: 424/130.100
 INCLS: 424/184.100
 NCL: 424/130.100
 IC [7] ICM: A61K039-395
 ICS: A61K039-395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 55 OF 63 USPATFULL
 AN 2001:173390 USPATFULL
 TI Transgenic non-human animals for producing heterologous antibodies
 IN Lomberg, Nils, Redwood City, CA, United States
 Key, Robert M., San Francisco, CA, United States
 PA GenPharm International, Palo Alto, CA, United States (U.S. corporation)
 PI US 6300129, B1 20011009
 AI US 1996-758417, 19961202 (8)
 RLI Continuation-in-part of Ser. No. US 1996-728863, filed on 10 Oct 1996
 Continuation-in-part of Ser. No. US 1995-544404, filed on 10 Oct 1995,
 now patented, Pat. No. US 5570429 Continuation-in-part of Ser. No. US
 1994-352322, filed on 7 Dec 1994, now patented, Pat. No. US 5625126
 Continuation-in-part of Ser. No. US 1994-203741, filed on 9 Mar 1994,
 now abandoned Continuation-in-part of Ser. No. US 1993-15699, filed on
 10 Dec 1993, now abandoned Continuation-in-part of Ser. No. US
 1993-161739, filed on 3 Dec 1993, now abandoned Continuation-in-part of
 Ser. No. US 1993-15501, filed on 18 Nov 1993, now abandoned
 Continuation-in-part of Ser. No. US 1993-98762, filed on 22 Jul 1993,
 now patented, Pat. No. US 5614318 Continuation-in-part of Ser. No. US

1993-53131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016
 Continuation-in-part of Ser. No. US 1992-990560, filed on 16 Dec 1992,
 now patented, Pat. No. US 554806 Continuation-in-part of Ser. No. US
 1992-904068, filed on 23 Jun 1992, now abandoned Continuation-in-part of
 Ser. No. US 1992-53408, filed on 18 Mar 1992, now patented, Pat. No. US
 5789650 Continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec
 1991, now patented, Pat. No. US 556925 Continuation-in-part of Ser. No.
 US 1990-575962, filed on 31 Aug 1990, now abandoned Continuation-in-part
 of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned
 Utility
 DT FS GRANTED
 LN,CNT 10030
 INCL: 435/326.000
 INCLS: 435/346.000; 435/354.000; 530/387.100; 800/003.000; 800/006.000;
 NCL: 435/325.000
 NCIS: 800/018.000
 IC [7] ICM: C12N015-86
 EXF 800/3; 800/6; 800/18; 435/326; 435/346; 435/354; 530/387.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 56 OF 63 USPATFULL
 AN 2001:144906 USPATFULL
 TI Treatment of B cell malignancies using anti-CD40L antibodies in
 combination with anti-CD20 antibodies and/or chemotherapeutics and
 radiotherapy
 IN Hanna, Nabil, Rancho Santa Fe, CA, United States
 Haribhan, Kandasamy, San Diego, CA, United States
 PA IDEC Pharmaceuticals Corporation (U.S. corporation)
 PI US 2001018041, A1 20010830
 AI US 2001-83433, A1 20010416 (9)
 RLI Division of Ser. No. US 1999-435992, filed on 8 Nov 1999, PENDING
 DT Utility
 FS APPLICATION
 LN,CNT 1728
 INCL: 424/001.490
 INCLS: 424/181.100
 NCL: 424/001.490
 NCIS: 424/181.100
 IC [7] ICM: A61K039-395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1 ANSWER 57 OF 63 USPATFULL
 AN 2001:131342 USPATFULL
 TI Conjugates of dithiocarbamate disulfides with pharmacologically active
 agents and uses therefor
 IN Lai, Ching-San, Encinitas, CA, United States
 Vassilev, Vassil, P., San Diego, CA, United States
 Wang, Tingmin, San Marcos, CA, United States
 PA Mediob, Inc., San Diego, CA, United States (U.S. corporation)
 PI US 6224627, B1 2001014
 AI US 1990-416619 19991012 (9)
 DT Utility
 FS GRANTED
 LN,CNT 2173
 INCL: 514/599.000
 INCLS: 514/706.000; 514/707.000
 NCL: 514/599.000
 NCIS: 514/706.000; 514/707.000
 IC [7]

ICN: A61K031-16
ICS: A61K031-055; A61K031-105
EXF 514/599; 514/706; 514/707
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 58 OF 63 USPATFULL
AN 2001:02988 USPATFULL
TI High affinity human antibodies and human antibodies against digoxin
IN Lönberg, Nils, Woodside, CA, United States
KY, Robert M., San Francisco, CA, United States
PA GenPharm International, San Jose, CA, United States (U.S. corporation)
PI US 6225458
RLI AI Continuation-in-part of Ser. No. US 1993-42353
Continuation-in-part of Ser. No. US 1996-758417, filed on 2 Dec 1996
Continuation-in-part of Ser. No. US 1996-728463, filed on 10 Oct 1996
now patented, Pat. No. US 5770429 Continuation-in-part of Ser. No. US 1994-52322, filed on 7 Dec 1994, now patented, Pat. No. US 5625126
Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994, now abandoned Continuation-in-part of Ser. No. US 1993-165699, filed on 10 Dec 1993, now abandoned Continuation-in-part of Ser. No. US 1993-61739, filed on 3 Dec 1993, now abandoned Continuation-in-part of Ser. No. US 1993-55301, filed on 18 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1993-96762, filed on 22 Jul 1993, now patented, Pat. No. US 5814318 Continuation-in-part of Ser. No. US 1993-33131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016 Continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992, now patented, Pat. No. US 5545806 Continuation-in-part of Ser. No. US 1992-904058, filed on 23 Jun 1992, now abandoned Continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992, now patented, Pat. No. US 5789650 Continuation-in-part of Ser. No. US 1992-834339, filed on 5 Feb 1992, now patented, Pat. No. US 5633425 Continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 556925 Continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned DT UTILITY FS GRANTED LN.CNT 10059
INC1M: 530/388-150
NCL: 530/388.150
NC1S: 435/326.000; 530/388-900
IC [7] ICM: C07K016-00
EX F 424/15.1; 435/336; 435/346; 435/345; 530/388-9; 530/388-15
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 59 OF 63 USPATFULL
AN 2000:141878 USPATFULL
TI Recombinant anti-CD4 antibodies for human therapy
IN Hanna, Nabil, Olivenehain, CA, United States
Newman, Roland Anthony, San Diego, CA, United States
Reff, Mitchell Elliott, San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 6136310
AI US 1995-523084
RLI Continuation-in-Part of Ser. No. US 1995-47237, filed on 7 Jun 1995, now patented, Pat. No. US 5556096 which is a continuation-in-part of Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US 565870 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned

continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility FS Granted LN.CNT 3398
INCL INCLM: 424/154.100
INCL INCLS: 530/387.300; 424/133.100; 424/141.100
INCL NCLM: 424/154.100
INCL NCLS: 424/133.100; 424/141.100; 530/387.300
IC [7] ICM: A61K039-395
EXF 530/387.3; 424/133.1; 424/141.1; 424/154.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 60 OF 63 USPATFULL
AN 2000:95042 USPATFULL
TI Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
IN Iai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
PA Mediox Inc., San Diego, CA, United States (U.S. corporation)
PI US 603743
AI US 1998-103639
DT Utility FS Granted LN.CNT 2691
INCL INCLM: 514/599.000
INCL INCLS: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000;
NCL NCLM: 514/866.000; 514/909.000; 514/912.000
NCL NCLS: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000;
IC [7] ICM: A61K031-16
ICL ICS: A61K031-095; A61K031-105
EXF 514/99; 514/707; 514/851; 514/861; 514/863; 514/909; 514/912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 61 OF 63 USPATFULL
AN 2000:1981 USPATFULL
TI Gamma-1 anti-human CD23 monoclonal antibodies
IN Reff, Mitchell E., San Diego, CA, United States
Kloetzer, William S., Carlsbad, CA, United States
Nakamura, Takehiko, Higashimamato, Japan
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
Seikagaku Corporation, Japan (non-U.S. corporation)
PI US 601138
AI US 1997-803085
DT Utility FS Granted LN.CNT 2519
INCL INCLM: 530/388-220
INCL INCLS: 530/387.300; 530/388-200; 530/388-150; 530/388-730; 530/389-600;
NCL NCLM: 530/387.900; 424/133.100; 424/139.100; 424/142.100; 424/144.100;
NCL NCLS: 424/153.100; 424/173.100; 424/172.100; 435/007.240; 435/069.600;
NCL NCLM: 424/169.200; 435/070.200; 435/326.000; 435/331.000; 435/332.000;
NCL NCLS: 424/133.100; 424/139.100; 424/142.100; 424/144.100; 424/153.100;
NCL NCLM: 424/172.100; 424/173.100; 435/007.240; 435/069.600; 435/069.700;
NCL NCLS: 424/133.100; 424/139.100; 424/142.100; 424/144.100; 424/153.100;
NCL NCLM: 424/172.100; 424/173.100; 435/007.240; 435/069.600; 435/069.700;
NCL NCLS: 424/133.100; 424/139.100; 424/142.100; 424/144.100; 424/153.100;

435/343. 100; 530/397.300; 530/387.900; 530/388.150; 530/388.200;
 530/388.730; 530/389.600

IC [6] ICM: A61K019-395
 EXP ICS: C12N005-22; C12N005-22; C07K016-28
 530/387.14; 530/387.3; 530/388.22; 530/388.2; 530/389.6; 424/643.1;
 424/113.1; 424/143.1; 424/139.1; 424/142.1; 424/144.1; 424/153.1;
 435/69.6; 435/69.7; 435/328; 435/334; 435/172.3; 435/7.24; 435/70.21;
 435/331; 435/343.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 62 OF 63 USPATFULL
 AN 1999-72602 USPATFULL
 TI Conjugates of dithiocarbamates with pharmacologically active agents and
 uses therefore
 IN Iai, Ching-San, Encinitas, CA, United States
 PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
 PI US 5316910
 AI US 1997-869158 1990629 (8)
 DT Utility
 FS Granted
 LN CNT 1842
 INCL INCL: 514/423.000
 INCUS: 514/514.000; 548/564.000; 548/573.000; 558/235.000
 NCL NCL: 514/514.000; 548/564.000; 548/573.000; 558/235.000
 IC ICM: C07D207-04
 EXP 514/514; 514/423; 548/565; 548/573; 558/235
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 63 OF 63 USPATFULL
 AN 1990-57523 USPATFULL
 TI Recombinant antibodies for human therapy
 IN Newman, Roland A., San Diego, CA, United States
 Hanna, Nabil, Olivemain, CA, United States
 Rabin, Ronald W., San Diego, CA, United States
 PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
 PI US 5750969 19980526
 AI US 1995-476237 19950507 (8)
 DT Continuation-in-part of Ser. No. US 1995-379072, filed on 25 Jan 1995, now parented, Pat. No. US 5658570 which is a continuation of Ser. No. US 1992-912292, filed on 10 July 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
 FS Utility
 LN CNT Granted
 INCL INCL: 424/1154.100
 INCUS: 424/113.100; 424/141.100; 530/387.100
 NCL NCL: 424/1154.100
 INCUS: 424/113.100; 424/141.100; 530/387.100
 IC [6] ICM: A61K039-395
 EXP 424/113.1; 424/141.1; 424/154.1; 530/387.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his
 (FILE 'HOME' ENTERED AT 12:17:32 ON 25 JUN 2002)

FILE 'MEDLINE', CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPATFULL, ENTERED AT
 12:18:32 OM 25 JUN 2002

11 63 S CE9.1
 L2 0 S 11 NOT PY=>1991
 L3 39370 S CHIMER? AND ANTIBOD?
 L4 5562 PRIMATE AND HUMAN AND L3
 L5 1188 S CD4 AND L4
 L6 4708 S L3 AND CD4
 L7 121 S 16 NOT PY=1991
 L8 62 DUP REM L7 (59 DUPLICATES REMOVED)
 => d 18 1-62

L8 ANSWER 1 OF 62 CAPLUS COPYRIGHT 2002 ACS
 AN 1990-629546 CAPLUS
 DN 113-229546
 TI Chimeric and mosaic antibodies to Leu 3a antigen
 IN Hinton, Robert; Li, Vernon T.
 PA Beeton, Dickinson and Co., USA
 SO Eur. Pat. Appl., 12 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1
 PATENT NO.----- KIND DATE----- APPLICATION NO. DATE-----
 PI ----- A2 19900425 ----- EP 1989-310415 19890111
 EP 365209 A3 19900725 -----
 R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
 JP 0228883 A2 19900921 J P 1989-270152 19891017
 PRAI US 1988-260558 19881017
 L8 ANSWER 2 OF 62 USPATFULL
 AN 90-67552 USPATFULL
 TI Genes and their encoded proteins which regulate gene expression of the
 Interleukin-2 receptor and of human lymphoproliferic retroviruses
 IN Cantor, Harvey I., Wellesley, MA, United States
 Patraca, Roberto, Brookline, MA, United States
 Dana-Farber Cancer Institute, Boston, MA, United States (U.S. corporation)
 PI US 4952499 19900828
 AI US 1988-154758 19880211 (7)
 DT Utility
 FS Granted
 LN CNT 1340
 INCL INCL: 435/172.300
 INCUS: 435/091.000; 435/172.100; 435/320.000; 435/252.330; 435/240.200;
 NCL NCL: 435/069.100
 INCUS: 435/069.100
 NCL: 435/252.330; 435/320.100; 435/358.000; 435/372.300; 435/455.000;
 IC [5] ICM: C12P021-00
 ICS: C12P021-02; C12P019-34; C12N015-00
 EXP 435/60; 435/70; 435/91; 435/172.1; 435/172.3; 435/320; 530/350; 536/27;
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LB ANSWER 3 OF 62 USPATFULL
 AN 90-38221 USPATFULL
 TI Detection and treatment of infectious and inflammatory lesions
 IN Hansen, Hans J., Westfield, NJ, United States
 Goldenberg, Milton D., Short Hills, NJ, United States

PA	Immunomedics, Inc., Warren, NJ, United States (U.S. corporation)	AN	90278062	MEDLINE
PI	US 4925648	DN	90278062	PubMed ID: 1972161
AI	US 1988-226180	TI		Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies.
DT	Utility Granted	AU	Alters S E; Sakai K; Steinman L; Oi V T	Program in Cancer Biology, Stanford University School of Medicine, CA 94305.
FS		CS		
LN	INCL	NC	CA-39502 (NCTI)	
CNT	991	TI	RO1NS18235 (NINDS)	
INCL	INDLM: 424/001 100 INCLS: 424/009, 800; 424/085, 910; 530/389, 000; 530/402, 000;	AU	JOURNAL OF IMMUNOLOGY, (1990 Jun 15) 144 (12) 4587-92.	
INCL	424/001, 530 252/001, 000	TI	Journal code: 2985117R. ISSN: 0022-1767.	
NCL	424/009, 340; 424/136, 100; 424/153, 100; 424/154, 100;	SO	United States	
INCL	424/178, 100; 530/388, 700; 530/388, 750; 530/389, 600;	CY	Journal; Article; (JOURNAL ARTICLE)	
INCL	530/391, 300; 530/402, 000; 530/866, 000	DT	Journal; Article; (JOURNAL ARTICLE)	
INCL	ICM: A61K019-02	LA	English	
INCL	ICC: A61K019-00; A61K039-395	FS	Abridged Index Medicus Journals; Priority Journals	
INCL	424/1, 1; 424/9; 424/85, 91; 424/85, 8; 530/387; 530/388; 530/389; 530/402;	EM	Entered STN: 199007	
INCL	252/1	ED	Entered STN: 19900824	
INCL	ANSWER 4 OF 62	DUPLICATE 1	Last Updated on STN: 20000303	
INCL	MEDLINE	DN	Entered Medline: 19900718	
INCL	91012791	TI		
INCL	PubMed ID: 1976822	AN	91050926	MEDLINE
INCL	Lymphocyte subset alterations and viral determinants of immunodeficiency disease induction by the feline leukemia virus FeLV-FAINS.	DN	91060926	PubMed ID: 2147194
INCL	Quarkebush S L; Donahue P R; Dean G A; Myles M H; Ackley C D; Cooper M D; Mullins J I; Hoover E A	TI	Concomitant administration of haptens and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones.	
INCL	Department of Pathology, Colorado State University, Fort Collins 80523.	AU	Bastos M G; Panzica P; Rubin-Kelley V E; Murphy J R; Strom T B	
INCL	AI-25273 (NIAID)	CS	Boston, MA 02115	
INCL	CA-43216 (NCTI)	SO	JOURNAL OF IMMUNOLOGY, (1990 Dec 1) 145 (11) 3535-9.	
INCL	JOURNAL OF VIROLOGY, (1990 Nov) 64 (11) 5465-74.	TI	Journal code: 2985117R. ISSN: 0022-1767.	
INCL	Journal code: 0022-538X.	SO	United States	
INCL	United States	CY	Journal; Article; (JOURNAL ARTICLE)	
INCL	Journal; Article; (JOURNAL ARTICLE)	DT	Journal; Article; (JOURNAL ARTICLE)	
INCL	English	LA	English	
INCL	Priority Journals; AIDS	FS	Abridged Index Medicus Journals; Priority Journals	
INCL	Entered STN: 19910117	EM	Entered STN: 19910117	
INCL	Last Updated on STN: 19950206	ED	Entered STN: 19910222	
INCL	Entered Medline: 19901115	TI	Last Updated on STN: 19910222	
INCL	Entered Medline: 19900718	AN	91050926	MEDLINE
INCL	DUPLICATE 2	DN	91060926	PubMed ID: 2147194
INCL	ANSWER 5 OF 62	TI	Concomitant administration of haptens and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones.	
INCL	MEDLINE	AU	Bastos M G; Panzica P; Rubin-Kelley V E; Murphy J R; Strom T B	
INCL	90311331	CS	Boston, MA 02115	
INCL	PubMed ID: 2142306	SO	JOURNAL OF IMMUNOLOGY, (1990 Dec 1) 145 (11) 3535-9.	
INCL	Human immunodeficiency virus infection is efficiently mediated by a glycolipid-anchored form of CD4.	TI	Journal code: 2985117R. ISSN: 0022-1767.	
INCL	DIAMOND D C; Finberg R; Chaudhuri S; Slectman B P; Busakoff S J	CY	United States	
INCL	Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA	DT	Journal; Article; (JOURNAL ARTICLE)	
INCL	02115	LA	English	
INCL	English	FS	Abridged Index Medicus Journals; Priority Journals	
INCL	Entered STN: 19910117	EM	Entered STN: 19910117	
INCL	Last Updated on STN: 19910117	ED	Entered STN: 19910117	
INCL	Entered Medline: 19900718	TI	Entered Medline: 19900718	
INCL	DUPLICATE 4	AN	91050926	MEDLINE
INCL	ANSWER 7 OF 62	DN	91060926	PubMed ID: 2147194
INCL	MEDLINE	TI	Concomitant administration of haptens and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones.	
INCL	DUPLICATE 2	AU	Bastos M G; Panzica P; Rubin-Kelley V E; Murphy J R; Strom T B	
INCL	ANSWER 8 OF 62	CS	Boston, MA 02115	
INCL	BIOSIS	SO	JOURNAL OF IMMUNOLOGY, (1990 Dec 1) 145 (11) 3535-9.	
INCL	1990:346757	TI	Journal code: 2985117R. ISSN: 0022-1767.	
INCL	BA39-42018	DT	United States	
INCL	CONSTRUCTION EXPRESSION AND FUNCTIONAL ANALYSIS OF A CHIMERIC ALPHA-CD4 CHIMERIC OKT4A ANTIBODY.	LA	Journal; Article; (JOURNAL ARTICLE)	
INCL	COLLINS A; PULITO V; GARRISON L; TRINKER S; VARGA S; OLSEN W; GHOBRIAL I; MCBRIDE M; SCHRELL J; ET AL	FS	English	
INCL	JOINT MEETING OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, AND THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, NEW ORLEANS, LOUISIANA, USA, JUNE 4-7, 1990. FASEB (FED AM SOC EXP BIOL) J, (1990) 4 (7), A2085.	ED	Journal; Article; (JOURNAL ARTICLE)	
INCL	CODEN: FASEC. ISSN: 0892-6638.	TI	Journal; Article; (JOURNAL ARTICLE)	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	PubMed ID: 2209702
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	PubMed ID: 2209702
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MEDLINE
INCL	Priority Journals; AIDS	DN	91006312	MEDLINE
INCL	Entered STN: 19900921	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Last Updated on STN: 19970203	AN	91006312	MEDLINE
INCL	Entered Medline: 19900815	DN	91006312	MEDLINE
INCL	Priority Journals; AIDS	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered STN: 19900921	AN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	DN	91006312	MEDLINE
INCL	Entered Medline: 19900815	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Priority Journals; AIDS	AN	91006312	MEDLINE
INCL	Entered STN: 19900921	DN	91006312	MEDLINE
INCL	Last Updated on STN: 19970203	TI	The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.	
INCL	Entered Medline: 19900815	AN	91006312	MED

SO	DEPARTMENT OF IMMUNOLOGY, Kyushu University, Fukuoka, Japan.
EUROPEAN JOURNAL OF IMMUNOLOGY, (1990 Sep) 20 (9) 2005-13.	Journal code: 1273201. ISSN: 0014-2980.
CY	GERMANY: Germany, Federal Republic of
DT	Journal; Article; (JOURNAL ARTICLE)
LA	English
FS	Priority Journals
EM	Entered STN: 1990111 Last Updated on STN: 19901117 Entered Medline: 19901121
L8	ANSWER 10 OF 62 MEDLINE
AN	9034179 PubMed ID: 1656594 A T cell receptor V alpha region selectively expressed in CD4+ cells.
DN	TI
AU	Jameson S C; Kaye J; Gascogne N R Department of Immunology, Research Institute of Scripps Clinic, La Jolla, CA 92037.
CS	GM-39476 (NIGMS)
SO	JOURNAL OF IMMUNOLOGY, (1990 Sep 1) 145 (5) 1324-31. Journal code: 2985117R. ISSN: 0022-1767.
CY	United States
DT	Journal; Article; (JOURNAL ARTICLE)
LA	English
FS	Abridged Index Medicus Journals; Priority Journals
ED	Entered STN: 19901025 Last Updated on STN: 19960129 Entered Medline: 19900920
L8	ANSWER 11 OF 62 MEDLINE
AN	90217939 PubMed ID: 2139098 Strong T cell tolerance in Parent-->F1 bone marrow chimeras prepared with supralethal irradiation. Evidence for clonal deletion and anergy.
DN	TI
AU	Gao E K; Lo D; Sprent J Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037.
CS	AI-21487 (NIH)
NC	CA-25853 (NCI)
SO	JOURNAL OF EXPERIMENTAL MEDICINE, (1990 Apr 1) 171 (4) 1101-21. Journal code: 2985109R. ISSN: 0022-1007. United States Journal; Article; (JOURNAL ARTICLE)
CY	English
DT	Priority Journals
LA	Entered STN: 19900632 Last Updated on STN: 19900522 Entered Medline: 19900517
L8	ANSWER 12 OF 62 MEDLINE
AN	91190787 MEDLINE
DN	TI
AU	Cell division-associated expression of an epitope, KHL7, on early developing thymocytes.
CS	Sano K; Kishimoto H; Karasuyama H; Asano Y; Tada T Department of Immunology, Faculty of Medicine, University of Tokyo, Japan.
SO	INTERNATIONAL IMMUNOLOGY, (1990) 2 (8) 725-33. Journal code: 89316182. ISSN: 0953-8178
CY	ENGLAND: United Kingdom
DT	Journal; Article; (JOURNAL ARTICLE)
LA	English
FS	Priority Journals
EM	Entered STN: 9910602 Last Updated on STN: 19970203 Entered Medline: 19910514
L8	ANSWER 13 OF 62 CAPLUS COPYRIGHT 2002 ACS
AN	1991:90475 CAPLUS
DN	115:90475
TI	Molecular mapping of immunogenic determinants of human CD4 using chimeric interspecies molecules and anti-CD4 antibodies
AU	Estss, Pila; Salmon, Sharon L.; Winberg, Margaret; Oi, Vernon T.; David
CS	Becton Dickinson Monoclonal Cent., Mountain View, CA, 94039, USA
SO	Curr. Res. Protein Chem.: Tech., Struct., Funct., [Pap. Annu. Symp. Protein Soc.], 3rd (1990), Meeting Date 1989, 499-508. Editor(s): Villaranca, Joseph J. Publisher: Academic, San Diego, Calif.
DT	Conference
LA	English
L8	ANSWER 14 OF 62 MEDLINE
AN	9031541 PubMed ID: 212440
DN	SO
TI	Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
AU	Champain R; Ho W; Gajewski J; Feig S; Burnison M; Holley G; Greenberg Lee K; Schmid I; Giorgi J; +
CS	Division of Hematology/Oncology, UCLA Center for Health Sciences. CA-23175 (NCT)
NC	RR005865 (NCRR)
TI	BLOOD, (1990 Jul 15) 76 (2) 418-23. Journal code: 7603509. ISSN: 0006-4971.
SO	United States
CY	Journal; Article; (JOURNAL ARTICLE)
DT	English
LA	Abridged Index Medicus Journals; Priority Journals
FS	Entered STN: 19900921 Last Updated on STN: 19900921 Entered Medline: 19900817
EM	Entered STN: 19900522 Last Updated on STN: 19900517
L8	ANSWER 15 OF 62 MEDLINE
AN	90321469 PubMed ID: 2196903
DN	TI
AU	Expression and characterization of human CD4:immunoglobulin fusion proteins.
CS	Zettlmeissl G; Gregersen J P; Duport J M; Mehdi S; Reiner G; Seed B
SO	Research Laboratories of Behringwerke AG, Marburg, West Germany.
TI	Journal code: 9004522. ISSN: 1044-5498.
CY	United States
DT	Journal; Article; (JOURNAL ARTICLE)
LA	English
FS	Priority Journals; AIDS
EM	Entered STN: 19901012 Last Updated on STN: 19970203 Entered Medline: 19900829

LB ANSWER 16 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 1990:111619 BIOSIS
 DN DAIRY HISTORY OF MIXED CHIMERISM AFTER BONE MARROW TRANSPLANTATION WITH CD6-DEPLETED ALLOGENIC MARROW A STABLE EQUILIBRIUM.
 AU ROY D C; TANTRAVAHY R; MURRAY C; DEAR K; GORGONE B; ANDERSON K C; FREEDMAN A S; NDLER L M; RITZ J
 CS DANA-FARBER CANCER INST., 44 BINNEY ST., BOSTON, MASS. 02115.
 SO BLOOD, (1990) 75(1), 297-304.
 CODEN: BLOODW. ISSN: 0006-4971.
 FS BA; OLD
 LA English

LB ANSWER 17 OF 62 MEDLINE
 9010597 MEDLINE
 DN
 TI Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium.
 AU Roy D C; Tantravahy R; Murray C; Dear K; Gorgone B; Anderson K C; Freedman A S; Nadler L M; Ritz J
 CS Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115.
 NC N01-Al-62531
 SO BLOOD, (1990 Jan 1) 75 (1) 296-304.
 Journal code: 7603509. ISSN: 0006-4971.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 19902
 TI Entered STN: 19900328
 Last Updated on STN: 19950206
 Entered Medline: 19900209

LB ANSWER 18 OF 62 MEDLINE
 AN 90227722 MEDLINE
 DN
 TI Natural suppressor cells in spleens of irradiated, bone marrow-reconstituted mice and normal bone marrow: lack of Sca-1 expression and enrichment by depletion of Mac-1-positive cells.
 AU Sykes M; Sharabi Y; Sachs D H
 CS Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
 SO CELLULAR IMMUNOLOGY, (1990 May) 127 (2) 260-74.
 CY Journal code: 1246405. ISSN: 0008-8749.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199005
 TI Entered STN: 19900706
 Last Updated on STN: 19950206
 Entered Medline: 19900331

LB ANSWER 19 OF 62 MEDLINE
 AN 91130709 MEDLINE
 DN
 TI Simian infection of macaque and mangabey monkeys: correlation between in vivo and in vitro properties of different isolates.
 AU Fultz P N; Anderson D C; McClure H M; Dernurst S; Mullins J I
 CS Yerkes Regional Primate Research Center, Atlanta, GA.
 CA-85007 (NIH)
 AN A1-85007 (NIH)
 SO RR-00165 (NCRR)

SO DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, (1990) 72 253-8.
 AN Journal code: 0427140. ISSN: 0301-5149.
 CY Switzerland
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; AIDS
 EM 199103
 TI Entered STN: 19910405
 Last Updated on STN: 19970203
 Entered Medline: 19910320

LB ANSWER 20 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 9191130377 BIOSIS
 DN
 TI IN-VITRO AND IN-VIVO CHARACTERISTICS OF A CHIMERIC HUMAN-MOUSE MONOCLONAL CD4 ANTIBODY.
 AU REITER C; FEUCHT H; RIEBER E P; DALESANDRO M; GRAYEB J; DADDONA P; RIEHMUELLER G
 CS INST. IMMUNOL., UNTV. MUNICH, 8000 MUECHEN, FRG.
 CY XXI MEETING OF THE SOCIETY OF IMMUNOLOGY, AACHEN, GERMANY, SEPTEMBER 12-16, 1990. IMMUNOBIOLOGY. (1990) 181 (2-3), 219-220.
 SO CODEN: IMMND4. ISSN: 0171-2985.
 DT Conference
 FS BA; OLD
 LA English

LB ANSWER 21 OF 62 MEDLINE
 AN 90293680 MEDLINE
 DN
 TI Specific tolerance induction across a xenogeneic barrier: production of mixed rat/mouse lymphohematopoietic chimeras using a nonlethal preparative regimen.
 AU Sharabi Y; Aksent'jevich I; Sundt T M 3rd; Sachs D H; Sykes M
 CS Transplantation Biology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1990 Jul 1) 172 (1) 195-202.
 CY Journal code: 2985109R. ISSN: 0022-1007.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199008
 TI Entered STN: 19900907
 Last Updated on STN: 19950206
 Entered Medline: 19900801

LB ANSWER 22 OF 62 MEDLINE
 AN 90324622 MEDLINE
 DN
 TI Determination of mixed chimerism by a simple flow cytometry method.
 AU Leenarts P L; Vandepitte M; Waer M
 CS Division of Nephrology, University of Leuven, Belgium.
 SO JOURNAL OF IMMUNOLOGICAL METHODS, (1990 Jul 3) 130 (2) 163-9.
 CY Netherlands
 CY Journal code: 1305440. ISSN: 0022-1759.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199008
 TI Entered STN: 19901012
 Last Updated on STN: 19901012
 Entered Medline: 19900824

LA	ANSWER 23 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.	CS	Department of Neurology and Genetics, Stanford University, California
AN	1990:412737 BIOSIS	AN	94305; JOURNAL OF CLINICAL IMMUNOLOGY, (1990 Nov) 10 (6 SUPPL) 30S-38S;
DN	BN:39:166758	DN	Journal code: 8102137. ISSN: 0271-9142.
TI	A PHASE I CLINICAL TRIAL WITH CHIMERIC ANTI-CD4 MONOClonal ANTIBODY IN PATIENTS WITH MYCOSIS FUNGOIDES.	TI	United States
MO	KNOX S J; HODGKINSON S; BELL B; BROWN S; WOOD G; HOPPE R; ABEL A A;	MO	Journal; Article; (JOURNAL ARTICLE)
SO	STEINMAN L; HANHAM A; ET AL	SO	(GENERAL REVIEW; (REVIEW)
CS	STANFORD UNIV. SCH. MED., STANFORD, CALIF.	CS	English, Tutorial,
SYNPOSUM ON CELLULAR IMMUNITY AND THE IMMUNOTHERAPY OF CANCER HELD AT THE 19TH ANNUAL UCLIA (UNIVERSITY OF CALIFORNIA-LOS ANGELES) SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY, PARK CITY, UTAH, USA, JANUARY 27-FEBRUARY 3, 1990. J CELL BIOCHEM SUPPL. (1990) 0 (14 PART B), 108.	SYNPOSUM ON CELLULAR IMMUNITY AND THE IMMUNOTHERAPY OF CANCER HELD AT THE 19TH ANNUAL UCLIA (UNIVERSITY OF CALIFORNIA-LOS ANGELES) SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY, PARK CITY, UTAH, USA, JANUARY 27-FEBRUARY 3, 1990. J CELL BIOCHEM SUPPL. (1990) 0 (14 PART B), 108.	ED	General Review; (Review)
CODEN: JCSD7.		ED	Entered STN: 19910526
DT	Conference	ED	Last Updated on STN: 20000303
FS	BR; OLD	ED	Entered Medline: 19910509
LA	English	ED	Entered Medline: 19910509
LA	ANSWER 24 OF 62 MEDLINE	LA	ANSWER 27 OF 62 MEDLINE
AN	91201985 MEDLINE	AN	90226048 MEDLINE
DN	CYTOXIC T LYMPHOCYTE RECOGNITION OF THE H-2-erbB HYBRID GENE PRODUCT LACKING THE COMPLETE H-2 DOMAIN STRUCTURE.	DN	90226048 PubMed ID: 2109590
TI	91201985 PubMed ID: 1708275	TI	A CD 4: immunoglobulin fusion protein with antiviral effects against HIV.
AU	DING L; ISobe K; IWAMOTO T; YOSHIDA T; Nagase F; Kawashima K; Nakashima I	AU	GRERERSEN J P; Mehdli S; GELDERBLOM H; ZETTLMEISSEL G
SO	DEPARTMENT OF IMMUNOLOGY, Nagoya University School of Medicine, Japan.	SO	RESEARCH LABORATORIES, Behringwerke AG, Marburg, Federal Republic of Germany
CY	INTERNATIONAL IMMUNOLOGY, (1990) 2 (1) 91-7.	CY	ARCHIVES OF Virology, (1990) 111 (1-2) 29-43.
ENGLAND: United Kingdom	JOURNAL code: 8916182. ISSN: 0953-8178.	ENGLAND: United Kingdom	Journal code: 7506870. ISSN: 0304-8608.
DT	Journal; Article; (JOURNAL ARTICLE)	DT	Journal; Article; (JOURNAL ARTICLE)
LA	English	LA	English
FS	PRIORITY JOURNALS	FS	PRIORITY JOURNALS
EM	199105	EM	199105
ED	Entered STN: 19910616	ED	Entered STN: 19910526
ED	Last Updated on STN: 19970203	ED	Last Updated on STN: 19970203
ED	Entered Medline: 19910529	ED	Entered Medline: 19910529
LA	ANSWER 25 OF 62 MEDLINE	LA	ANSWER 28 OF 62 CAPLUS
AN	91008471 MEDLINE	AN	1990:37060 CAPLUS
DN	91008471 PubMed ID: 221189	DN	112:137060
TI	CYTOTOXIC AND PROLIFERATIVE T-CELL CLONES WITH ANTIDONOR REACTIVITY FROM A PATIENT TRANSPLANTED FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE.	TI	A COMPARISON OF RAT AND RAT-MOUSE CHIMERIC ANTI-MURINE CD4 ANTIBODIES FOR USE IN IMMUNOTHERAPY
AU	KEEVER C A; FLOMENBERG N; Gazzola M V; PEKLE K; YANG S Y; SMALL T N;	AU	ALTERS, SUSAN ELLEN
CS	COLLINS N H; O'REILLY R J; BONE MARROW TRANSPLANTATION SERVICE, MEMORIAL SLOAN-KETTERING CANCER CENTER, NEW YORK, NEW YORK.	CS	STANFORD UNIV., STANFORD, CA, USA
NC	CA-08748 (NCI)	NC	(1989), 98 PP. AVAIL.: UNIV. MICROFILMS INT., ORDER NO. DA8925820
CA-33050 (NCI)	CT5732C09512-02 (DERT)	DT	FROM: DISS. ABSTR. INT. B 1990, 50(7), 2830
SO	HUMAN IMMUNOLOGY, (1990 SEP) 29 (1) 42-55.	DT	Dissertation
CY	JOURNAL CODE: 8010336. ISSN: 0198-8859.	ED	Entered Medline: 19900521
DT	UNITED STATES	ED	Entered Medline: 19900521
LA	JOURNAL; ARTICLE; (JOURNAL ARTICLE)	ED	Entered Medline: 19900521
FS	PRIORITY JOURNALS	ED	Entered Medline: 19900521
EM	199011	ED	Entered Medline: 19900521
ED	Entered STN: 19910117	ED	Entered Medline: 19900521
ED	Last Updated on STN: 19960129	ED	Entered Medline: 19900521
ED	Entered Medline: 19901116	ED	Entered Medline: 19900521
LA	ANSWER 26 OF 62 MEDLINE	LA	ANSWER 29 OF 62 CAPLUS
DN	91185511 MEDLINE	DN	1990:156563 CAPLUS
TI	THE USE OF MONOCLONAL ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASE.	TI	IMPROVEMENTS RELATING TO THE PRODUCTION OF MONOCLONAL ANTIBODIES USING CHIMERIC PROTEINS
IN	STEINMAN L	IN	BODMER, WALTER FRED; BODMER, JULIA GYNAETH; MADDOK, JILL FAYE; REYNOLDS, GARY
PA	IMPERIAL CANCER RESEARCH TECHNOLOGY LTD., UK	PA	IMPERIAL CANCER RESEARCH TECHNOLOGY LTD., UK
SO	PCT Int. Appl., 30 pp.	SO	PCT Int. Appl., 30 pp.
CODEN: PIXD2		CODEN: PIXD2	
DT	PATENT	DT	PATENT
LA	ENGLISH	LA	ENGLISH
LA	FAN, CNT 1	LA	FAN, CNT 1
LA	PATENT NO. _____	LA	PATENT NO. _____
LA	KIND _____	LA	KIND _____
LA	DATE _____	LA	DATE _____
LA	APPLICATION NO. _____	LA	APPLICATION NO. _____
LA	DATE _____	LA	DATE _____
PI	WO 8904871 A1	PI	WO 8904871 A1
W	JP, US	W	JP, US
RW	AT, BE, CH, DE, FR, GB, IT, LU, NL, SE	RW	AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

PRAI	GB	1987-27030	19871118	
LB	ANSWER	30 OF 62 MEDLINE	DUPLICATE 17	
AN	8931834	MEDLINE		
DN	8931834	PubMed ID: 2501790		
TI	Cell proliferation and thymocyte subset reconstitution in sublethally irradiated mice: compared kinetics of endogenous and intrathymically transferred progenitors.			
AU	Penit C; Ezine S			
CS	Institut National de la Santé et de la Recherche Médicale, Unité 25, Centre National de la Recherche Scientifique Unité Associée 122, Hôpital Necker, Paris, France.			
SO	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1989 July) 86 (14) 5547-51.			
CY	Journal code: 7505876. ISSN: 0027-8424.			
CR	United States			
DT	Journal; Article; (JOURNAL ARTICLE)			
LA	English			
FS	Priority Journals			
EM	198908			
ED	Entered STN: 19900309			
	Last Updated on STN: 19970203			
	Entered Medline: 19890816			
LB	ANSWER	31 OF 62 MEDLINE	DUPLICATE 17	
AN	89286649	MEDLINE		
DN	89286649	PubMed ID: 2200662		
TI	Positive selection of a T-cell subpopulation in the thymus in which it develops.			
AU	Iwabuchi K; Negishi I; Arase H; Iwabuchi C; Ogasawara K; Good R A; Onoe K			
CS	Institute of Immunological Science, Hokkaido University, Japan.			
NC	AG05628 (NIA)			
SO	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1989 July) 86 (13) 5099-93.			
CY	Journal code: 7505876. ISSN: 0027-8424.			
DT	Journal; Article; (JOURNAL ARTICLE)			
LA	English			
FS	Priority Journals			
EM	198908			
ED	Entered STN: 19900309			
	Last Updated on STN: 19970203			
	Entered Medline: 19890810			
LB	ANSWER	32 OF 62 MEDLINE	DUPLICATE 18	
AN	90078997	MEDLINE		
DN	90078997	PubMed ID: 2480382		
TI	A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells.			
AU	Tsui W; Liou R S; Rosen E M; Fung M S; Sun W N; Sun C; Gordon W; Chang N T; Chang			
CS	Tanox Biosystems, Inc., Houston, TX 77025.			
SO	JOURNAL OF IMMUNOLOGY, (1989 Dec 15) 143 (12) 3967-75.			
CY	Journal code: 2985117R. ISSN: 0022-1767.			
DT	United States			
LA	English			
FS	Abridged Index Medicus Journals; Priority Journals; AIDS			
EM	199001			
ED	Entered STN: 19900328			
	Last Updated on STN: 19970203			
	Entered Medline: 19900119			
LB	ANSWER	33 OF 62 MEDLINE	DUPLICATE 19	
AN	8925187	MEDLINE		
DN	89235187	PubMed ID: 2523932		
TI	Immune dysfunction associated with graft-vs-host reaction in mice transplanted across minor histocompatibility barriers. II. Reversible defect in T-dependent antibody responses.			
AU	Buddecha S; Hamilton B L			
CS	Department of Biological Structure, University of Washington, Seattle NC 98155.			
NC	CA-22757 (NCI)			
SO	JOURNAL OF IMMUNOLOGY, (1989 Jun 1) 142 (11) 3740-5.			
CY	Journal code: 2985117R. ISSN: 0022-1767.			
DT	United States			
LA	English			
FS	Abridged Index Medicus Journals; Priority Journals			
EM	199006			
ED	Entered STN: 19900306			
	Last Updated on STN: 19970203			
	Entered Medline: 19890822			
LB	ANSWER	34 OF 62 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.	DUPLICATE 19	
AN	89280094	EMBASE		
DN	1989260094			
TI	Rejection of skin allografts by CD4+ T cells is antigen-specific and requires expression of target antigen on La- epidermal cells.			
AU	Rosenberg A-S; Katz S I; Singer A			
CS	Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20292, United States			
SO	Journal of Immunology, (1989) 143/8 (2452-2456).			
NC	ISSN: 0022-1767 CODEN: JOMA3			
SO	United States			
CY	Journal			
DT	026 Immunology, Serology and Transplantation			
LA	English			
FS	English			
SL	English			
LB	ANSWER	35 OF 62 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.	DUPLICATE 19	
AN	90010439	EMBASE		
DN	1990010439			
TI	Positive and negative selection of T cell receptor V(beta) domains controlled by distinct cell populations in the thymus.			
AU	Spaizer D; Lees R K.; Hengartner H.; Zinkernagel R M.; Macdonald H R			
CS	Institute of Pathology, University Hospital, 8091 Zurich, Switzerland			
SO	Journal of Experimental Medicine, (1989) 170/6 (2165-2170).			
DN	ISSN: 0022-1007 CODEN: JEMEAV			
TI	United States			
DT	Journal; Article			
LA	English			
FS	026 Immunology, Serology and Transplantation			
SL	English			
LB	ANSWER	36 OF 62 MEDLINE	DUPLICATE 20	
AN	89156469	MEDLINE		
DN	89156469	PubMed ID: 2466082		
TI	Comparison of rat and rat-mouse chimeric anti-murine CD4 antibodies in vitro. Chimeric antibodies lyse low-density CD4+ cells.			
AU	Alters S E; Steinman L; Oi V T			
CS	Program in Cancer Biology, Stanford University School of Medicine, CA 94305.			
NC	CA-03102 (NCI)			
SO	ROINS18235 (NINDS)			

SO	JOURNAL OF IMMUNOLOGY, (1989 Mar 15) 142 (6) 2018-23.	Entered STN: 9900328 Last Updated on STN: 19900328 Entered Medline: 19900103
DT	Journal; Article; (JOURNAL ARTICLE)	
LA	English	
EM	Abridged Index Medicus Journals; Priority Journals	
ED	Entered STN: 19900306 Last Updated on STN: 19970203 Entered Medline: 19890417	
L8	ANSWER 37 OF 62 MEDLINE 89341374 MEDLINE 89341374 Published ID: 2788186 Journal code: 278511R. ISSN: 0022-1167.	
AU	Ramadell F; Fowlkes B J	
LA	Laboratory of Cellular and Molecular Immunology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.	
SO	JOURNAL OF IMMUNOLOGY, (1989 Sep 1) 143 (5) 1467-71.	
EM	Journal code: 278511R. ISSN: 0022-1167.	
CY	United States	
DT	Journal; Article; (JOURNAL ARTICLE)	
LA	English	
FS	Abridged Index Medicus Journals; Priority Journals	
ED	Entered STN: 19900309 Last Updated on STN: 19900309 Entered Medline: 19890913	
L8	ANSWER 38 OF 62 MEDLINE 8938040 MEDLINE 89378040 PubMed ID: 2528461	DUPPLICATE 21
AU	Cytoklastic CD3+ surface CD8+ lymphocytes develop as a thymus-independent lineage in chick-quail chimeras.	
LA	Bucy R P; Colley M; Chen C I; Char D; Le Douarin N M; Cooper M D	
FS	Department of Pathology, University of Alabama, Birmingham 35294.	
ED	Entered STN: 19900309 Last Updated on STN: 19900309 Entered Medline: 19890913	
L8	ANSWER 39 OF 62 MEDLINE 90069560 MEDLINE 90069560 Published ID: 2511629	DUPPLICATE 21
AU	A nondeletional mechanism of thymic self tolerance.	
LA	Ramsdell F; Lantz T; Fowlkes B J	
CS	Laboratory of Cellular and Molecular Immunology, National Institute of Allergy and Infectious Disease, Bethesda, MD 20892.	
SO	SCIENCE, (1989 Nov 24) 246 (4933) 1038-41.	
EM	Journal code: 004511. ISSN: 0036-8075.	
CY	United States	
DT	Journal; Article; (JOURNAL ARTICLE)	
LA	English	
FS	Priority Journals	
ED	Entered STN: 19900101 Last Updated on STN: 19970203 Entered Medline: 19890101	
L8	ANSWER 40 OF 62 MEDLINE 89176864 MEDLINE 89176864 PubMed ID: 2647894	DUPPLICATE 21
AU	Qin S X; Cobbold S; Benjamin R; Waldmann H	
LA	Department of Pathology, University of Cambridge, United Kingdom.	
SO	JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Mar 1) 169 (3) 779-94.	
ED	Entered STN: 19900306 Last Updated on STN: 19900306 Entered Medline: 19890424	
L8	ANSWER 41 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC. 8919438073 BIOSIS 8919438073 PubMed ID: 2647894	DUPPLICATE 21
AU	Mizukami T; Smith C D; Breret E A; Moss B	
LA	LAB. VIRAL DIS., NATL. ALLERGY AND INFECTIOUS DIS., NATL. INST. HEALTH, BETHESDA, MD 20292.	
SO	MORISSET, R. A. (ED.). VI CONFERENCE INTERNATIONALE SUR LE SIDA: LE DEFI SCIENTIFIQUE ET SOCIAL; V INTERNATIONAL CONFERENCE ON AIDS: THE SCIENTIFIC AND SOCIAL CHALLENGE; MONTREAL, QUEBEC, CANADA, JUNE 4-9, 1989. 126P. INTERNATIONAL DEVELOPMENT RESEARCH CENTRE: OTTAWA, ONTARIO, CANADA. ILLUSTRATED PAPER. (1989) 0 (0), 556.	
ED	Entered STN: 19900306 Last Updated on STN: 19900306 Entered Medline: 19890424	
L8	ANSWER 42 OF 62 MEDLINE 9022782 MEDLINE 9022782 PubMed ID: 2516640	DUPPLICATE 22
AU	Lessons from past experience in cancer immunotherapy and their application to cancer and AIDS treatment and prophylaxis.	
LA	Mathe G	
CS	Institut du Cancer et d'Immunogenetique, Immunotherapies et Tumeurales, Hopital Paul-Brousse, Villejuif, France.	
SO	BIOMEDICINE AND PHARMACOTHERAPY, (1989) 43 (8) 551-61. Ref: 112	
ED	Entered STN: 19900306 Last Updated on STN: 19900306 Entered Medline: 19890424	
L8	ANSWER 43 OF 62 MEDLINE 89094246 MEDLINE 89094246 Published ID: 2562984	DUPPLICATE 23
AU	General Review; (REVIEW, TUTORIAL)	
LA	English	
FS	Priority Journals; AIDS	
ED	Entered STN: 19900632 Last Updated on STN: 19970203 Entered Medline: 19900514	

TI Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen.
 AU Sharabi Y; Sachs D H
 CS Transplantation Biology Section, National Cancer Institute, Bethesda, Maryland 20292.
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Feb 1) 169 (2) 493-502.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198902
 ED Entered STN: 19900308
 Last Updated on STN: 19950206
 Entered Medline: 19890221

TI ANSWER 44 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1989:257214 BIOSIS
 DN BR38:124438
 TI COMPARISON OF RAT AND RAT-MOUSE CHIMERIC ANTIMURINE CD4 ANTIBODIES FOR USE IN IMMUNOTHERAPY.
 AU ALTERS S; STEINMAN L; OI V
 CS STANFORD UNIV. SCH. MED., STANFORD, CALIF. 94305
 SO 73RD ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, NEW ORLEANS, LOUISIANA, USA, MARCH 19-23, 1989.
 FASB (FED AM SOC EXP BIOL) J. (1989) 3 (3), A492.
 CODEN: FAJOSC. ISSN: 0892-6638.
 DT Conference
 LA English
 FS OLD
 BR: OLD
 English

TI ANSWER 45 OF 62 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 1990:1469 EMBASE
 DN 19905169
 TI Persistence of the irradiated host component in thymocyte populations from bone marrow radiations chimeras infected with lymphocytic choriomeningitis virus.
 AU Lynch F.; Ceredig R.; Hartley D.; Doherty P.C.
 CS Department of Experimental Pathology, The John Curtin School of Medical Research, Canberra, ACT, Australia
 SO Cellular Immunology, (1989) 110(2) (482-490).
 ISSN: 0008-8749 CODEN: CLIMB8
 CY United States
 DT Journal
 FS 026 Immunology, Serology and Transplantation
 LA English
 SL English

TI ANSWER 46 OF 62 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:116919 CAPLUS
 DN 112:116919
 TI Production and properties of chimeric antibody molecules
 AU Shin, Seung Won; Morrison, Sherie L.
 CS Mol. Biol. Inst., Univ. California, Los Angeles, CA, 90024, USA
 SO Methods Enzymol. (1989), 178 (Antibodies, Antigens, Mol. Mimicity), 459-76
 CODEN: MENZAU; ISSN: 0076-6879
 DT Journal
 LA English
 SL English

TI ANSWER 47 OF 62 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1990:84459 BIOSIS
 DN BR38:40049

TI IMMUNOPATHOLOGY OF MYCOSIS FUNGOIDES MF PATIENTS TREATED WITH CHIMERIC ANTI-GD4 ANTIBODY.
 AU WOOD G S; KNOX S; BNDL J; HOPPE R T; ABEL E A; WARNKE R A; LEVY R
 CS STANFORD UNIV., STANFORD, CALIF., USA
 SO 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF DERMATOPATHOLOGY, SAN FRANCISCO, CALIFORNIA, USA, NOVEMBER 29-DECEMBER 1, 1989. J CUTANEOUS PATHOL. (1989) 16 (5), 330.
 CODEN: JCUPBN. ISSN: 0303-6987.
 DT Conference
 LA English
 FS Priority Journals
 BR: OLD
 English

TI ANSWER 48 OF 62 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 89231146 EMBASE
 DN 198251146
 TI Monocyte function after bone marrow transplantation: Role of Ia+ monocytes in graft-versus-host disease.
 AU Bezvoda W.R.; Danys R.
 CS Department of Medicine, Hematology/Oncology, University of the Witwatersrand, Johannesburg, South Africa
 SO Clinical Transplantation, (1989) 3/5 (264-268).
 ISSN: 0802-0063 CODEN: CLTRD
 CY Denmark
 DT Journal
 FS 025 Hematology
 LA English
 SL English

TI ANSWER 49 OF 62 MEDLINE
 AN 89203262 MEDLINE
 DN 89203262
 TI Influence of the major histocompatibility complex on positive thymic selection of V beta 17a⁺ T cells.
 AU Blackman M A; Marrack P; Kappler J
 CS Howard Hughes Medical Institute, Denver, CO.
 SO SCIENCE, (1989 Apr 14) 244 (4901) 214-7.
 CODEN: SCIEAM
 DT Journal
 LA English
 FS Priority Journals
 EM 198905
 ED Entered STN: 19900306
 Last Updated on STN: 19900306
 Entered Medline: 19890512

DUPLICATE 24

TI ANSWER 50 OF 62 MEDLINE
 AN 89080484 MEDLINE
 DN 89080484
 TI Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance inducing method using cyclophosphamide.
 AU Matsumi H; Good R A
 CS Division of Cardiovascular Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
 NC AG-05628 (NIAID)
 AI-22360 (NIAID)
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Jan 1) 169 (1) 213-38.
 CODEN: JEMDI
 DT Journal
 LA English
 FS Priority Journals
 BR: OLD
 English

TI ANSWER 51 OF 62 MEDLINE
 AN 89080485 MEDLINE
 DN 89080485
 TI Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance inducing method using cyclophosphamide.
 AU Matsumi H; Good R A
 CS Division of Cardiovascular Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
 NC AG-05628 (NIAID)
 AI-22360 (NIAID)
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Jan 1) 169 (1) 213-38.
 CODEN: JEMDI
 DT Journal
 LA English
 FS Priority Journals

EM 198902 Entered STN: 19900308
ED Last Updated on STN: 19970203
Entered Medline: 19890209

L8 ANSWER 51 OF 62 MEDLINE
AN 91137503 MEDLINE
DN 91137503 Published ID: 2518657
TI Preferential expansion of Ly-1⁺ B and CD4⁻ CD8⁻ T cells in the polyclonal lymphocyte responses to murine *T. cruzi* infection. *AU* Minoprio P; Bandeira A; Pereira P; Mota Santos T; Coutinho A
CS DEPARTMENT OF IMMUNOLOGY, Pasteur Institute, Paris, France.
SO Journal code: 8916182. ISSN: 0953-8178.
CY ENGLAND: United Kingdom
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199103 Entered STN: 19910412
LA Last Updated on STN: 19910412
FS Entered Medline: 19910322

L8 ANSWER 52 OF 62 MEDLINE
AN 90007595 MEDLINE
DN 90007595 Published ID: 2793201
TI Donor and recipient specific tolerance in cells from semi-allogeneic, H-2 subregion compatible or fully allogeneic bone marrow chimeras attributable to clonal deletion. *AU* Onoe K; Iwabuchi K; Iwabuchi C; Arase H; Hatakeyama S; Wambua P P; Fukushi N; Negishi T; Good R A; Ogasawara K
CS Section of Pathology, Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
NC AG05628 (NIAID)
AT22360 (NIAID)
SO IMMUNOBIOLOGY, (1989 Jun) 179 (2-3) 172-89.
CY Journal code: 8002142. ISSN: 0171-2985.
DT GERMANY, WEST: Germany, Federal Republic of
LA Journal: Article; (JOURNAL ARTICLE)
FS Priority Journals
EM 198911 Entered STN: 19900328
ED Last Updated on STN: 19970203
Entered Medline: 19891120

L8 ANSWER 53 OF 62 MEDLINE
AN 89310351 MEDLINE
DN 89310351 Published ID: 2501444
TI Positive selection determine T cell receptor γ beta 14 gene usage by CD8⁺ T cells. *AU* Liao N S; Maltzman J; Raulet D H
CS Center for Cancer Research, Massachusetts Institute of Technology, Cambridge 02139.
NC CA-28900 (NCI)
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Jul 1) 170 (1) 135-43.
CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198908 Entered STN: 19900309
ED Last Updated on STN: 19970203

Entered Medline: 19890811
ED
DUPLICATE 28

L8 ANSWER 54 OF 62 MEDLINE
AN 89080475 MEDLINE
DN 89080475 Published ID: 2562946
TI Restricted tissue distribution of Mlsa determinants. Stimulation of Mla-reactive T cells by B cells but not by dendritic cells or macrophages. *AU* Webb S R; Okamoto A; Ron Y; Sprent J
CS Research Institute of Scripps Clinic, La Jolla, California 92037.
CA-25803 (NCI)
CA-38355 (NCI)
CA-41993 (NCI)
+ JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Jan 1) 169 (1) 1-12.
Journal code: 2985109R. ISSN: 0022-1007.
CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198902 Entered STN: 19900308
ED Last Updated on STN: 19970203
Entered Medline: 19890209

L8 ANSWER 55 OF 62 USPATFULL
AN 88:7/1003 USPATFULL
TI Expression and diagnostic use of PENY-3 encoded peptides which are immunologically reactive with antibodies to LAV
IN Watanabe, Susan M., Seattle, WA, United States
Cosand, Wesley L., Bothell, WA, United States
McArdle, Susan, Seattle, WA, United States
Travis, Bruce M., Seattle, WA, United States
PA Genetic Systems Corporation, Seattle, WA, United States (U.S. corporation)
PI US 478491 19881115
AI US 478578329 19851002 (6)
RLI Continuation-in-part of Ser. No. US 1985-721237, filed on 8 Apr 1985
DT Utility Granted
FS
LN CNT 835
INCL INC1M: 435/005.000
INCL INC1S: 435/007.000; 435/070.000; 436/531.000; 436/811.000; 530/324.000;
NCL NCLM: 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000
NCL NCLS: 435/069.500; 435/974.000; 436/531.000; 436/811.000; 530/324.000;
NCL 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;
IC [4] ICM: G01N033-545
ICM: G01N033-53; C12Q001-70
EXF 435/5; 435/7; 436/53; 436/811; 530/324-329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8 ANSWER 56 OF 62 USPATFULL
AN 88:2601 USPATFULL
TI Biologically functional molecular chimeras
IN Cohen, Stanley N., Menlo Park, CA, United States
PA Boyer, Herbert W., Mill Valley, CA, United States
PA The Board of Trustees of the Leland Stanford, Jr. University, Stanford, CA, United States (U.S. corporation)
PI US 4740470 1980425
AI US 1984-602294
US 1984-602294
RLI Continuation of Ser. No. US 1978-959288, filed on 9 Nov 1978, now

patented, Pat. No. US 4468464 which is a continuation of Ser. No. US 1976-68730, filed on 17 May 1976, now abandoned which is a continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974, now abandoned

DT Utility
FS Granted
LN.CNT 982
INCL INCLM: 435/172.300
INCUS: 435/091.000; 435/320.000; 435/240.200; 435/253.000; 935/027.000;
NCL NCLM: 435/031.000; 935/032.000
NCLS: 435/066.000; 435/091.100; 435/252.300; 435/252.310; 435/252.330;
IC [4] ICM: C12N015-00
EXF 435/172.3; 435/91; 435/317; 435/253; 435/240; 435/320; 435/240.2;
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 57 OF 62 CAPLUS COPYRIGHT 2002 ACS
AN 1988-471673 CAPLUS
DN 109-71673
TI The envelope glycoprotein of the human immunodeficiency virus binds to the immunoproloubulin-like domain of CD4
AU Landau, Nathaniel R.; Warton, Mari; Littman, Dan R.
CS Howard Hughes Med. Inst., Univ. California, San Francisco, CA, 94143, USA
SO Nature (London) (1988), 334(618), 159-62
CODEN: NATUAS; ISSN: 0028-0836

DT Journal
LA English

DN ANSWER 58 OF 62 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 88208625 EMBASE
DN 1988208625
TI Cyclosporine-induced pseudo-graft-versus-host disease in the early post-cyclosporine period.
AU Beachner, W.E.; Shinn, C.A.; Fischer, A.C.; Santos, G.W.; Hess, A.D.
CS The Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD
SO 21205, United States
TRANSPANTATION, (1988) 46(2 SUPPL. (112S- 117S)).
ISSN: 0041-1337 CODEN: TRPLAU

DT United States
CY Journal
FS General Pathology and Pathological Anatomy
005
026
037
037
LA Drug Literature Index
ENGLISH
SL English

DN ANSWER 59 OF 62 MEDLINE
AN 88080506 MEDLINE
DN 88080506
TI Cyclosporine and the thymus: influence of irradiation and age on thymic immunopathology and recovery.
AU Beachner, W.E.; Di Gennaro, K.A.; Hess, A.D.; Santos, G.W.
CS Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
NC AT24319 (NIAID)
CA15396 (NCI)
CA28701 (NCI)
SO CELLULAR IMMUNOLOGY, (1987 Dec) 110 (2) 350-64.
CY Journal code: 1246405. ISSN: 0008-8749.
United States

DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198802
ED Entered STN: 19900305
Entered Medline: 19880202
Last Updated on STN: 19970203

LN.CNT 841
INCL INCLM: 530/324.000
INCUS: 530/325.000; 530/326.000; 530/403.000
NCL NCLM: 530/324.000
NCLS: 530/005.000; 435/068.100; 435/069.200; 435/961.000; 435/974.000;
PA 530/325.000; 530/326.000; 530/403.000; 930/221.000; 930/DIG.802;
930/DIG.811; 930/DIG.821
IC [4] ICM: C07K007-10
ICS: C07K017-00
EXF 260/112.5R; 530/324; 530/325; 530/403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 60 OF 62 USPATFULL
AN 86-71616 USPATFULL
TI Synthetic antigen for the detection of AIDS-related disease
IN Cosand, Wesley L.; Bothell, WA, United States
PA Genetic Systems Corporation, Seattle, WA, United States (U.S. corporation)
PI US 4329783
AI 19861216
RLI Continuation-in-part of Ser. No. US 1985-728052, filed on 29 Apr 1985,
now abandoned-in-part of Ser. No. US 1985-728052, filed on 29 Apr 1985,
now abandoned
DT Utility
FS Granted
LN.CNT 841
INCL INCLM: 530/324.000
INCUS: 530/325.000; 530/326.000; 530/403.000
NCL NCLM: 530/324.000
NCLS: 530/005.000; 435/068.100; 435/069.200; 435/961.000; 435/974.000;
PA 530/325.000; 530/326.000; 530/403.000; 930/221.000; 930/DIG.802;
930/DIG.811; 930/DIG.821
IC [4] ICM: C07K007-10
ICS: C07K017-00
EXF 260/112.5R; 530/324; 530/325; 530/403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 61 OF 62 USPATFULL
AN 84-49479 USPATFULL
TI Biologically functional molecular chimeras
IN Cohen, Stanley N., Menlo Park, CA, United States
PA Boyer, Herbert W., Mill Valley, CA, United States
The Board of Trustees of The Leland Stanford Junior University,
Stanford, CA, United States (U.S. corporation)
PI US 4368464
AI 19840828
RLI Continuation of Ser. No. US 1976-68730, filed on 17 May 1976, now
abandoned which is a continuation-in-part of Ser. No. US 1974-520691,
filed on 4 Nov 1974, now abandoned
DT Utility
FS Granted
LN.CNT 885
INCL INCLM: 435/317.000
INCUS: 435/068.000; 435/253.000; 435/820.000; 435/172.300; 935/006.000;
NCL NCLM: 435/029.000; 935/056.000; 935/060.000; 935/067.000; 935/068.000;
NCLS: 435/073.000; 935/084.000; 535/023.000
IC [3] ICM: C12N001-00
ICS: C12N015-00; C12N001-20; C12B021-00
EXF 435/172; 435/68; 435/317; 435/91; 435/253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 62 OF 62 USPATFULL
AN 80-60508 USPATFULL
TI Process for producing biologically functional molecular chimeras
IN Cohen, Stanley N., Portola Valley, CA, United States

Boyer, Herbert W., Mill Valley, CA, United States
 Board of Trustees of the Leland Stanford Jr. University, Stanford, CA,
 United States (U.S. corporation)
 PI US 4237224 1978-10-21 19901202
 AI Continuation-in-part of Ser. No. US 1978-959288, filed on 9 Nov 1978;
 now Defensive Publication No. which is continuation-in-part of Ser.
 No. US 1976-687430, filed on 17 May 1976, now abandoned which is a
 continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974,
 now Defensive Publication No.
 DT Utility
 FS Granted
 LN CNT 983
 INCL INCLM: 435/068.000; 435/231.000; 435/083.000; 435/317.000; 435/849.000;
 INCLS: 435/172.000; 435/091.000; 435/207.000; 260/112.500S; 260/027.000;
 NCL NCLM: 435/069.100
 NCLS: 435/069.200; 435/069.300; 435/069.400; 435/069.500; 435/069.510;
 435/069.520; 435/059.600; 435/091.100; 435/091.400; 435/091.410;
 435/183.000; 435/207.000; 435/212.000; 435/231.000; 435/252.330;
 435/320.100; 435/820.000; 530/311.000; 530/397.000;
 IC [1] 530/399.000; 530/808.000; 536/023.100
 ICM: C12P021-00
 EKF 195/1; 195/28N; 195/28R; 195/112; 195/78; 195/79; 435/68; 435/172;
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his
 (FILE 'HOME' ENTERED AT 12:17:32 ON 25 JUN 2002)
 FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT
 12:18:32 ON 25 JUN 2002
 L1 63 S CEP9.1
 L2 0 S LI NOT PY=>1991
 L3 39370 S CHIMER? AND ANTIBOD?
 L4 5562 S PRIMATE AND HUMAN AND L3
 L5 1188 S CD4 AND L4
 L6 4108 S L3 AND CD4
 L7 421 S L6 NOT PY=>1991
 L8 62 DUP REM L7 (59 DUPLICATES REMOVED)

=> treatment and 16
 => treatment is not a RECOGNIZED COMMAND
 The previous command name entered was not recognized by the system.
 For a list of commands available to you in the current file, enter
 "HELP COMMANDS" at an arrow prompt (>).

=> s treat? and 16
 => s 19 not PY=>1991
 => 4 FILES SEARCHED..
 L10 44 L9 NOT 'PY=>1991
 => d 110 1-44

L10 ANSWER 1 OF 44 MEDLINE
 AN 9108531 MEDLINE
 DN 9108531 PubMed ID: 2891787
 TI The use of monoclonal antibodies for treatment of

autoimmune disease.
 Steinmann L AU
 Department of Neurology and Genetics, Stanford University, California CS
 94305.
 SO JOURNAL OF CLINICAL IMMUNOLOGY, (1990 Nov) 10 (6 Suppl) 30S-38S;
 disscusion 38S-39S. Ref: 21
 Journal code: 8102137. ISSN: 0271-9142.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW, TUTORIAL)
 (REVIEW, TUTORIAL)

LA
 FS Priority Journals
 EM
 ED Entered STN: 19910526
 Last Updated on STN: 20000303
 Entered Medline: 19910509

L10 ANSWER 2 OF 44 MEDLINE
 AN 91060926 MEDLINE
 DN 91060926 PubMed ID: 2147194
 TI Concomitant administration of antigen-hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones.
 AU Bastos M G; Panewitz O; Rubin-Kelley V E; Murphy J R; Strom T B
 CS Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA 02115.
 SO JOURNAL OF IMMUNOLOGY, (1990 Dec 1) 145 (11) 3535-9.
 CY Journal code: 2985117R. ISSN: 0022-1767.
 United States
 DR Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM
 ED Entered STN: 19910222
 Last Updated on STN: 19910222
 Entered Medline: 19910107

L10 ANSWER 3 OF 44 MEDLINE
 AN 91008471 MEDLINE
 DN 91008471 PubMed ID: 221189
 TI Cytotoxic and proliferative T-cell clones with antidionor reactivity from a patient transplanted for severe combined immunodeficiency disease.
 AU Keever C A; Flomenberg N; Gazzola M V; Pekle K; Yang S Y; Small T N;
 CS Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York, New York.
 NC CA-08748 (NCI)
 CA-33050 (NCI)
 CT5032C109512-02 (DCRT)
 SO HUMAN IMMUNOLOGY, (1990 Sep) 29 (1) 42-55.
 CY Journal code: 8010936. ISSN: 0198-6859.
 DT United States
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM
 ED Entered STN: 19910117
 Last Updated on STN: 19960129
 Entered Medline: 19901116

L10 ANSWER 4 OF 44 MEDLINE
 AN 91006312 MEDLINE
 DN 91006312 PubMed ID: 2209702
 TI The requirement of intrathymic mixed chimerism and clonal

deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.

AU Eto M; Mayumi H; Tomita Y; Yoshikai Y; Nishimura Y; Nomoto K
CS Department of Immunology, Kyushu University, Fukuoka, Japan.
SO EUROPEAN JOURNAL OF IMMUNOLOGY, (1990 Sep) 20 (9) 2005-13.
CY Journal code: 1273201. ISSN: 0014-2980.
DT Germany, Federal Republic of
LA Journal; Article; (JOURNAL ARTICLE)
FS Priority Journals
EM 199011
Entered STN: 19910117
Last Updated on STN: 19910117
Entered Medline: 19901121

L10 ANSWER 5 OF 44 MEDLINE
AN 9031541
DN 9031541
TI Selective depletion of CD4+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
AU Champin R; Ho W; Gajewski J; Feig S; Burnison M; Holley G; Greenberg P; Lee K; Schmid I; Giorgi J; +
CS Division of Hematology/Oncology, UCLA Center for Health Sciences, CA-23175 (NCI)
RR00805 (NCRR)
SO BLOOD, (1990 Jul 15) 76 (2) 418-23.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199008
Entered STN: 19900921
Last Updated on STN: 19900921
Entered Medline: 19900817

L10 ANSWER 6 OF 44 MEDLINE
AN 90278062
DN 90278062
TI PubMed ID: 1972161
Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies.
AU Alters S E; Sakai K; Steinman L; Oi V T
CS Program in Cancer Biology, Stanford University School of Medicine, CA 94305.
NC ROINS18235 (NINDS)
SO JOURNAL OF IMMUNOLOGY, (1990 Jun 15) 144 (12) 4587-92.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199007
Entered STN: 19900824
Last Updated on STN: 20000303
Entered Medline: 19890718

L10 ANSWER 7 OF 44 MEDLINE
AN 90212782
DN 90212782
TI Lessons from past experience in cancer immunotherapy and their application to cancer and AIDS treatment and prophylaxis.
AU Mathe G

L10 ANSWER 8 OF 44 MEDLINE
AN 90078997
DN 90078997
TI PubMed ID: 2480392
A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells.
AU Liou R S; Rosen E M; Fung M S; Sun W N; Sun C; Gordon W; Chang N T; Chang T W R; Tanox Biosystems, Inc., Houston, TX 77025.
CS JOURNAL OF IMMUNOLOGY, (1989 Dec 15) 143 (12) 3967-75.
SO Journal code: 2085117R. ISSN: 0022-1767.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; AIDS
EM 199001
Entered STN: 19900328
Last Updated on STN: 19970203
Entered Medline: 19900119

L10 ANSWER 9 OF 44 MEDLINE
AN 89176864
DN 89176864
TI PubMed ID: 2647894
Induction of classical transplantation tolerance in the adult.
AU Qin S X; Cobbold S; Benjamin R; Waldmann H
CS Department of Pathology, University of Cambridge, United Kingdom.
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Mar 1) 169 (3) 779-94.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198904
Entered STN: 19900306
Last Updated on STN: 19900306
Entered Medline: 19890424

L10 ANSWER 10 OF 44 MEDLINE
AN 89156469
DN 89156469
TI PubMed ID: 2466082
Comparison of rat and rat-mouse chimeric anti-murine CD4 antibodies in vitro. Chimeric antibodies lyse low-density CD4+ cells.
AU Alters S E; Steinman L; Oi V T
CS Program in Cancer Biology, Stanford University School of Medicine, CA 94305.
NC ROINS18235 (NINDS)
SO JOURNAL OF IMMUNOLOGY, (1989 Mar 15) 142 (6) 2018-23.
CY Journal code: 2985117R. ISSN: 0022-1767.

CY United States
 DR Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 198904
 ED Entered STN: 19900306
 Last Updated on STN: 19970203
 Entered Medline: 19890417

L10 ANSWER 11 OF 44 MEDLINE
 AN 89094246 MEDLINE
 DN 89094246 PubMed ID: 2562984
 TI Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal prepatative regimen.
 AU Sharabi Y; Sachs D H
 CS transplantation Biology Section, National Cancer Institute, Bethesda, Maryland 20892.
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Feb 1) 169 (2) 493-502.
 Journal code: 2985109R. ISSN: 0022-1007.

CY United States
 DR Journal; Article; (JOURNAL ARTICLE)
 LA English Journals
 FS Priority Journals
 EM 198902
 ED Entered STN: 19900308
 Last Updated on STN: 19950206
 Entered Medline: 19890221

L10 ANSWER 12 OF 44 MEDLINE
 AN 8908084 MEDLINE
 DN 8908084 PubMed ID: 2642528
 TI Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
 AU Mayumi H; Good R A
 CS Division of Cardiovascular Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
 NC AG-0528 (NIAID)
 AI-2266 (NIAID)

SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Jan 1) 169 (1) 213-38.
 Journal code: 2985109R. ISSN: 0022-1007.

CY United States
 DR Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198902
 ED Entered STN: 19900308
 Last Updated on STN: 19970203
 Entered Medline: 19890209

L10 ANSWER 13 OF 44 MEDLINE
 AN 8908075 MEDLINE
 DN 8908075 PubMed ID: 256846
 TI Restricted tissue distribution of Mlsa determinants. Stimulation of Mlsa-reactive T cells by B cells but not by dendritic cells or macrophages.
 AU Webb S R; Okamoto A; Ron Y; Sprent J
 CS Research Institute of Scripps Clinic, La Jolla, California 92037.
 NC CA-25803 (NCI)
 CA-38355 (NCI)
 CA-41993 (NCI)

SO JOURNAL OF EXPERIMENTAL MEDICINE, (1989 Jan 1) 169 (1) 1-12.
 Journal code: 2985109R. ISSN: 0022-1007.

CY United States
 DR Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198902
 ED Entered STN: 19900308
 Last Updated on STN: 19970203
 Entered Medline: 19890209

L10 ANSWER 14 OF 44 MEDLINE
 AN 8908056 MEDLINE
 DN 8908056 PubMed ID: 3500795
 TI Cyclosporine and the thymus: influence of irradiation and age on thymic immunopathology and recovery.
 AU Beschner W E; Di Gennaro K A; Hess A D; Santos G W
 CS Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
 NC AI-24319 (NIAID)
 CA15395 (NCI)
 CA38701 (NCI)

SO JOURNAL OF CELLULAR IMMUNOLOGY, (1987 Dec) 110 (2) 350-64.
 Journal code: 1246405. ISSN: 0008-8749.

CY United States
 DR Journal; Article; (JOURNAL ARTICLE)
 LA English Journals
 FS Priority Journals
 EM 198902
 ED Entered STN: 19900305
 Last Updated on STN: 19970203
 Entered Medline: 19880202

L10 ANSWER 15 OF 44 CANCERLIT
 AN 91000926 CANCERLIT
 DN 91000926
 TI Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones.
 AU Bastos M G; Pankewycz O; Rubinstein-Kelley V E; Murphy J R; Strom T B
 CS Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA 02115.
 SO JOURNAL OF IMMUNOLOGY, (1990). Vol. 145, No. 11, pp. 3535-9.
 Journal code: 1FB. ISSN: 0022-1767.

CY United States
 DR Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS MEDL; Abridged Index Medicus Journals; Priority Journals; Cancer Journals
 OS MEDLINE 91060926
 EM 199102

L10 ANSWER 16 OF 44 CANCERLIT
 AN 90315491 CANCERLIT
 DN 90315491
 TI Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
 AU Champlin R; Ho W; Gajewski J; Feig S; Burnison M; Holley G; Greenberg P; Lee K; Schmid I; Giorgi J; et al
 CS Division of Hematology/Oncology, UCLA Center for Health Sciences, CA-23175 (NCI)
 RR00865 (NCRR)

SO BLOOD, (1990), Vol. 76, No. 2, pp. 418-23.
 Journal code: ABG. ISSN: 0006-4971.

CY United States
 DR Journal; Article; (JOURNAL ARTICLE)
 LA English Journals

OS MEDLINE 9031541
EM 199009
L10 ANSWER 17 OF 44 CANCERLIT
AN 90212782
DN 90212782
TI Lessons from past experience in cancer immunotherapy and their application to cancer and AIDS treatment and prophylaxis.
AU Mathe G
CS Institut du Cancer et d'Immunogenetique, Immunitaires et Tumorales, Hopital Paul-Brousse, Villejuif, France.
SO BIOMEDICINE AND PHARMACOTHERAPY, (1989). Vol. 43, No. 8, pp. 551-61.
Journal code: A59, ISSN: 0753-332.
DR Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
FS MEDL; L; Priority Journals
LA English
OS MEDLINE 90212782
EM 199006

L10 ANSWER 18 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 91061964
DN 91061964
TI The use of monoclonal antibodies for treatment of autoimmune disease.
AU Steinman L.
CS Department of Neurology and Genetics, Stanford University, Stanford, CA 94305, United States
SO Journal of Clinical Immunology, (1990) 10/6 SUPPL. (30S-39S).
ISSN: 0271-9442 CODEN: JCIMD0
CY United States
DR Journal; Conference Article
AU 026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English

L10 ANSWER 19 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90256472
DN 1990256472
TI Cytotoxic and proliferative T-cell clones with antidonor reactivity from a patient transplanted for severe combined immunodeficiency disease.
AU Keever C.A.; Flomenberg N.; Gazzola M.V.; Pekle K.; Yang S.Y.; Small T.N.; Collins N.H.; O'Reilly R.J.
GS Div. Bone Marrow Transplant., Ohio State University, 410 W. 10th Avenue, Columbus, OH 43210, United States
SO Human Immunology, (1990) 29/1 (42-55).
CY United States
DR Journal; Article
AU 026 Immunology, Serology and Transplantation
LA English
SL English

L10 ANSWER 20 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90231399
DN 1990231399
TI Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
AU Champlyn R.; Ho W.; Gajewski J.; Feig S.; Burnison M.; Holley G.; Greenberg P.; Lee K.; Schmid I.; Giorgi J.; Yam P.; Petz L.; Winston D.; Warner N.; Reichert T.
CS Section of Bone Marrow, Transplantation, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, United States
SO Blood, (1990) 76/2 (418-423).
ISSN: 0006-4971 CODEN: BLOODA

CY United States
DT Journal; Article
AU 025 Hematology
FS 026 Immunology, Serology and Transplantation
LA English
SL English

L10 ANSWER 21 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90229954
DN 1990229954
TI Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies.
AU Alters S.E.; Sakai K.; Steinman L.; Oi V.T.
CS Program in Cancer Biology, Stanford University School of Medicine, Stanford, CA 94305, United States
SO Journal of Immunology, (1990) 144/12 (4587-4592).
ISSN: 0022-1767 CODEN: JOIMMA3

CY United States
DT Journal; Article
AU 026 Immunology, Serology and Transplantation
LA English
SL English

L10 ANSWER 22 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90078024
DN 1990078024
TI Lessons from past experience in cancer immunotherapy and their application to cancer and AIDS treatment and prophylaxis.
AU Mathe G.
CS Institut du Cancer et d'Immunogenetique and Departement des Maladies Sanguiines, Immunitaires et Tumorales, Hopital Paul-Brousse, 94800 Villejuif, France
SO Biomedicine and Pharmacotherapy, (1989) 43/8 (551-561).
ISSN: 0753-3322 CODEN: BIPHEX

CY France
DT Journal; Editorial
AU 016 Cancer
FS 026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL French; English

L10 ANSWER 23 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90012925
DN 1990012225
TI A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells.
AU Liu R.-S.; Roger E.M.; Fung M.S.C.; Sun W.N.C.; Sun C.; Gordon W.; Chang N.T.; Chang T.W.
CS Tanox Biosystems, Inc., 10301 Stella Link, Houston, TX 77025, United States
SO Journal of Immunology, (1999) 143/12 (3967-3975).
ISSN: 0022-1767 CODEN: JOIMMA3

CY United States
DT Journal; Article
AU 026 Immunology, Serology and Transplantation
FS 026 Immunology, Serology and Transplantation
LA English
SL English

L10 ANSWER 24 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 89081596

DN 1989081596
 TI Comparison of rat and rat-mouse chimeric anti-murine CD4
 low-density CD4+ cells. *in vitro*. **Chimeric antibodies lyse**

AU Alter S.E.; Steinman L.; OI V.T.
 CS Becton Dickinson Immunocytometry Systems, Mt. View, CA 94039, United States
 SO Journal of Immunology, (1989) 142/6 (2018-2023).
 ISSN: 0022-1767 CODEN: JOIMA3

CY United States
 DT Journal of Immunology, Serology and Transplantation
 FS 026 Immunology, Serology and Transplantation
 LA English
 SL English

L10 ANSWER 25 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 89050647 EMBASE
 DN 1989050647

TI Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen.

AU Sharabi Y.; Sachs D.H.
 CS Transplantation Biology Section, Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States
 SO Journal of Experimental Medicine, (1989) 169/2 (493-502).
 ISSN: 0022-1007 CODEN: JEMEAU

CY United States
 DT Journal of Hematology, Serology and Transplantation
 FS 025 Hematology
 LA 026 Immunology, Serology and Transplantation
 ST English

L10 ANSWER 26 OF 44 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 8905554 EMBASE
 DN 198903554

TI Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.

AU Mayumi H.; Good R.A.
 CS Division of Cardiovascular Surgery, Research Institute of Angiocardiology, Faculty of Medicine, Kyushu University, Fukuoka 812, Japan
 SO Journal of Experimental Medicine, (1989) 169/1 (213-238).
 ISSN: 0022-1007 CODEN: JEMEAU

CY United States
 DT Journal of Hematology, Serology and Transplantation
 FS 025 Hematology, Serology and Transplantation
 LA 026 Immunology, Serology and Transplantation
 ST English

L10 ANSWER 29 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1990:411144 BIOSIS
 DN BA90:7745

TI SELECTIVE DEPLETION OF CD8 POSITIVE T LYMPHOCYTES FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENIC BONE MARROW TRANSPLANTATION.

AU CHAMPLIN R; HO W; GAJERSKI J; FEIG S; BURNISON M; HOLLEY G; GREENBERG P;
 LEE K; SCHMID I; ET AL
 CS SECT. BONE MARROW TRANSPLANTATION, MD ANDERSON CANCER CENT., 1515 HOLCOMBE BLVD., HOUSTON, TEXAS 77030.
 SO BLOOD, (1990) 76 (2), 418-423.
 CODEN: BLOAA. ISSN: 0006-4971.

FS BA; OLD
 LA English

L10 ANSWER 30 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1990:380600 BIOSIS
 DN BA90:67281

TI MECHANISMS OF ANTI-CD4-MEDIATED DEPLETION AND IMMUNOTHERAPY A STUDY USING A SET OF CHIMERIC ANTI-CD4 ANTIBODIES.

AU ALTERS S E; SAKAI K; STEINMAN L; OI V T
 CS DEP. NEUROLOGY H-3160, STANFORD UNIVERSITY SCHOOL MEDICINE, STANFORD, CALIF. 94305-5225.
 SO J IMMUNOL, (1990) 144 (12), 4587-4592.
 CODEN: JOIMA3. ISSN: 0022-1767.

FS BA; OLD
 LA English

L10 ANSWER 31 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1990:9244 BIOSIS
 DN BA89:51995

TI A CHIMERIC MOUSE-HUMAN ANTIBODY THAT RETAINS SPECIFICITY FOR HIV GP120 AND MEDIATES THE LYSIS OF HIV-INFECTED CELLS.

AU LIOU R-S; ROSEN E R; FUNG M S C; SUN W N C; SUN C; GORDON W; CHANG N T; CHANG T W
 CS TANOX BIOSYSTEMS INC., 10301 STELLA LINK, HOUSTON, TEXAS 77025.
 SO J IMMUNOL, (1989) 143 (12), 3967-3975.
 CODEN: JOIMA3. ISSN: 0022-1767.

FS BA; OLD
 LA English

L10 ANSWER 32 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1990:81459 BIOSIS
 DN BR38:4049
 TI IMMUNOPATHOLOGY OF NYCOSIS FUNGOIDES MF PATIENTS TREATED WITH CHIMERIC ANTI-CD4 ANTIBODY.

AU WOOD G S; KNOX S; BINDL J; HOPPE R T; ABEL E A; WARNKE R A; LEVY R
 CS STANFORD UNIV.; STANFORD, CALIF., USA.
 SO 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF DERMATOPATHOLOGY, SAN
 FRANCISCO, CALIFORNIA, USA, NOVEMBER 29-DECEMBER 1, 1989. J CUTANEOUS
 PATHOL. (1989) 16 (5), 330.
 CODEN: JCUPBN. ISSN: 0303-6987.

DT Conference
 FS BR; OLD
 LA English

L10 ANSWER 33 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1989-224054 BIOSIS
 DN BA87-115671
 TI COMPARISON OF RAT AND RAT-MOUSE CHIMERIC ANTI-MURINE CD4
 ANTIODIES IN-VITRO CHIMERIC ANTIBODIES LYSE
 LOW-DENSITY CD4-POSITIVE CELLS.
 AU ALTERS S E; STEINMAN L; OI V T
 CS BECTON DICKINSON MONOCLOINAL CENT., 2375 GARCIA AVE., MOUNTAIN VIEW, CALIF.
 SO 94039, USA.
 J IMMUNOL. (1989) 142 (6), 2018-2023.
 CODEN: JOIMA3; ISSN: 0022-1767.
 FS BA; OLD
 LA English

L10 ANSWER 34 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1989-203337 BIOSIS
 DN BA87-104241
 TI MIXED CHIMERISM AND PERMANENT SPECIFIC TRANSPLANTATION TOLERANCE
 INDUCED BY A NONLETHAL PREPARATIVE REGIMENT.
 AU SHARABI Y; SACHS D H
 CS NATL. CANCER INST., NATL. INST. HEALTH, BUILDING 10, ROOM 4B17, BETHESDA,
 MD 20892, USA.
 SO J EXP MED. (1989) 169 (2), 493-502.
 CODEN: JEMEAV. ISSN: 0022-1007.

FS BA; OLD
 LA English

L10 ANSWER 35 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1989-136466 BIOSIS
 DN BA87-71119
 TI LONG-LASTING SKIN ALLOGRAFT TOLERANCE IN ADULT MICE INDUCED ACROSS FULLY
 ALLOGENIC MULTIMAJOR H-2 PLUS MULTIMINOR HISTOCOMPATIBILITY ANTIGEN
 BARRIERS BY A TOLERANCE-INDUCED METHOD USING CYCLOPHOSPHAMIDE.
 AU MAYUMI H; GOOD R A
 CS DIV. CARDIOVASCULAR SURGERY, RES. INST. ANGIOCARDIOL., FAC. MED., KYUSHI
 UNIV., 3-1-1 MAIDASHI, HIGASHI-KU, FUKUOKA 812, JPN.
 SO J EXP MED. (1989) 169 (1), 213-236.
 CODEN: JEMEAV. ISSN: 0022-1007.

FS BA; OLD
 LA English

L10 ANSWER 36 OF 44 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1989-132435 BIOSIS
 DN BA87-67588
 TI RESTRICTED TISSUE DISTRIBUTION OF Mls-A DETERMINANTS STIMULATION OF
 Mls-A-REACTIVE T CELLS BY B CELLS BUT NOT BY DENDRITIC CELLS OR
 MACROPHAGES.

AU WEBB S R; OKAMOTO A; RON Y; SPRENT J
 CS RES. INST. SCRIPPS CLIN., LA JOLLA, CALIF. 92037.
 SO J EXP MED. (1989) 169 (1), 1-12.
 CODEN: JEMEAV. ISSN: 0022-1007.

FS BA; OLD
 LA English

L10 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2002 ACS
 AN 1990-62546 CAPLUS
 DN 113-229546
 TI Chimeric and mosaic antibodies to Ieu 3a antigen
 IN Hinton, Robert; Oi, Vernon T.
 PA Becton, Dickinson and Co., USA
 SO Bur. Pat. Appl., 12 pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI EP 365209 A2 19900425 EP 1989-310415 19891011
 R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
 JP 02231883 A2 19900921 JP 1989-270152 19891017
 PRAI US 1988-260558
 PRAI US 1988-260558

L10 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2002 ACS
 AN 1990-493863 CAPLUS
 DN 113-95863
 TI Mechanisms of anti-CD4-mediated depletion and immunotherapy. A
 study using a set of chimeric anti-CD4
 antibodies.
 AU Alter, Susan E.; Sakai, Koichiro; Steinman, Lawrence; Oi, Vernon T.
 CS Sch. Med., Stanford Univ., Stanford, CA, 94305, USA
 SO J. Immunol. (1990) 144(12), 4587-92
 CODEN: JOIMA3; ISSN: 0022-1767

DT Journal
 LA English

L10 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2002 ACS
 AN 1990-116911 CAPLUS
 DN 112-116911
 TI A chimeric mouse-human antibody that retains
 specificity for HIV gp120 and mediates the lysis of HIV-infected cells
 AU Liou, Ruey Shyan; Rosen, Edward M.; Fung, Michael S. C.; Sun, William N.
 C.; Sun, Cecily; Gordon, Wayne; Chang, Nancy T.; Chang, Tse Wen
 CS Tanox Biosyst., Inc., Houston, TX, 77025, USA
 SO J. Immunol. (1989) 143(12), 3967-75
 CODEN: JOIMA3; ISSN: 0022-1767

DT Journal
 LA English

L10 ANSWER 40 OF 44 USPATFULL
 AN 90-67582 USPATFULL
 TI Genes and their encoded proteins which regulate gene expression of the
 interleukin-2 receptor and of human lymphotropic retroviruses
 IN Cantor, Harvey I.; Wellesley, MA, United States
 Patarea, Roberto, Brookline, MA, United States
 Dana-Farber Cancer Institute, Boston, MA, United States (U.S.
 PA corporation)
 PI US 4932499
 AT US 1988-154758
 DT 19880211 (7)
 FS Utility Granted
 LN.CNT 1340
 INCL INCLM: 435/172, 300
 INCLS: 435/091, 000; 435/172, 100; 435/320, 000; 435/252, 330; 435/240, 200;
 NCL NCIM: 435/069, 100
 NCIS: 435/252, 330; 435/320, 100; 435/358, 000; 435/372, 300; 435/455, 000;
 NCLS: 536/023, 520; 536/023, 720; 536/024, 100

IC [5] ICM: C12P021-00
IN ICM: Cohen, Stanley N., Menlo Park, CA, United States
IIS: C12R021-02; C12P019-34; C12N015-00
PA Boyer, Herbert W., Mill Valley, CA, United States
EXF 435/60; 435/70; 435/91; 435/172.1; 435/320; 530/350; 536/27;
The Board of Trustees of The Leland Stanford Junior University,
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 41 OF 44 USPATFULL
TI Detection and treatment of infectious and inflammatory lesions
IN Hansen, Hans J., Westfield, NJ, United States
PA Goldenberg, Milton D., Short Hills, NJ, United States
PT Immunomedics, Inc., Warren, NJ, United States (U.S. corporation)
US 4935648 19900515
US 1988-226180 19880729 (7)

AI Utility Granted
DT Utility filed on 4 Nov 1974, now abandoned
FS Granted

LN,CNT 991
INCL ICM: 424/001.100
INCL: 424/009.000; 424/085.800; 424/085.910; 530/389.000; 530/402.000;
NCL ICM: 252/001.000
NCLS: 252/001.000; 424/001.530
INCL ICM: 424/001.000; 424/009.340; 424/136.100; 424/153.100; 424/154.100;
424/178.100; 530/388.700; 530/388.730; 530/388.750; 530/389.600;
530/391.300; 530/402.000; 530/866.000

IC [5] ICM: A61K049-02
INCL ICM: A61K049-00; A61K039-395
EXF 424/1.1; 424/9; 424/85.91; 424/85.8; 530/387; 530/388; 530/389; 530/402;
252/1

L10 ANSWER 42 OF 44 USPATFULL
TI Biologically functional molecular chimeras
IN Cohen, Stanley N., Menlo Park, CA, United States
PA Boyer, Herbert W., Mill Valley, CA, United States
PT The Board of Trustees of the Leland Stanford Jr. University, Stanford,
CA, United States (U.S. corporation)
US 470470 19880426
AI US 1984-602294 19840420 (6)
RLI Continuation of Ser. No. US 1978-959288, filed on 9 Nov 1978, now
patented, Pat. No. US 4464649 which is a continuation of Ser. No. US
1976-687430, filed on 17 May 1976, now abandoned which is a
continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974,
now abandoned

DT Utility Granted
FS Granted

LN,CNT 982
INCL ICM: 435/172.300
INCL: 435/091.000; 435/320.000; 435/240.200; 435/253.000; 935/027.000;
NCL ICM: 435/031.000; 935/032.000
INCL ICM: 435/091.400; 435/091.410; 435/252.300; 435/252.310; 435/252.330;
435/320.100; 435/488.000; 536/023.100

IC [4] ICM: C12N015-00
INCL ICM: C12N005-00; C12N001-20; C12N001-00; C12P019-34
EXF 435/172.3; 435/91; 435/317; 435/253; 435/240; 435/320; 435/240.2;
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 43 OF 44 USPATFULL
IN 84:48179 USPATFULL
TI Biologically functional molecular chimeras

IN Cohen, Stanley N., Menlo Park, CA, United States
PA Boyer, Herbert W., Mill Valley, CA, United States
The Board of Trustees of The Leland Stanford Junior University,
Stanford, CA, United States (U.S. corporation)
PT US 4658464 19840828
AI US 1978-959288 19781109 (5)
RLI Continuation of Ser. No. US 1976-687430, filed on 17 May 1976, now
abandoned which is a continuation-in-part of Ser. No. US 1974-520691,
filed on 4 Nov 1974, now abandoned

DT Utility Granted
FS Granted

LN,CNT 885
INCL ICM: 435/317.000
INCL: 435/029.000; 435/253.000; 435/820.000; 435/172.300; 935/006.000;
935/073.000; 935/084.000; 535/023.000

IC [3] ICM: C12N001-00
INCL ICM: 435/320.100
INCL: 435/820.000

IN Cohen, Stanley N., Menlo Park, CA, United States
PA Boyer, Herbert W., Mill Valley, CA, United States
PT The Board of Trustees of The Leland Stanford Junior University, Stanford, CA,
United States (U.S. corporation)
US 4371724 19801202
RLI Continuation-in-part of Ser. No. US 1978-959288, filed on 9 Nov 1978,
now Defensive Publication No. which is a continuation-in-part of Ser.
No. US 1976-687430, filed on 17 May 1976, now abandoned which is a
continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974,
now Defensive Publication No.

DT Utility Granted
FS Granted

LN,CNT 983
INCL ICM: 435/068.000
INCL: 435/172.000; 435/231.000; 435/183.000; 435/317.000; 435/849.000;
435/820.000; 435/091.000; 435/207.000; 260/112.500S; 260/027.000

INCL ICM: 435/212.000
NCL ICM: 435/068.100
INCL ICM: 435/069.200; 435/069.300; 435/069.400; 435/069.500; 435/069.510;
435/069.520; 435/069.600; 435/091.100; 435/091.400; 435/091.410;
435/183.000; 435/207.000; 435/212.000; 435/211.000; 435/231.000; 435/252.330;
435/320.100; 435/220.000; 435/849.000; 530/311.000; 530/397.000;
530/399.000; 530/808.000; 536/023.100

IC [1] ICM: C12P021-00
EXF 435/221; 435/183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:17:32 ON 25 JUN 2002)
FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT
12:18:32 ON 25 JUN 2002

L1 63 S CE9_1
 L2 0 S L1 NOT PY=>1991
 L3 39370 S CHIMER? AND ANTI-BOD?
 L4 5562 S PRIMATE AND HUMAN AND L3
 L5 1388 S CD4 AND L4
 L6 1408 S L3 AND CD4
 L7 121 S L6 NOT PY=>1991
 L8 62 DUP REM L7 (59 DUPLICATES REMOVED)
 L9 3420 S TREAT? AND L6
 L10 44 S L9 NOT PY=>1991
 => s l10 and gamma 4
 L11 0 L10 AND GAMMA 4
 => s l10 and ce9gamma4pe
 L12 0 L10 AND CE9GAMMA4PE
 => s ce9gamma4pe
 L13 0 CE9GAMMA4PE
 => s l1s l10 and transplant rejection
 MISSING OPERATOR l1s l10
 The search profile that was entered contains terms or
 nested terms that are not separated by a logical operator.
 => s l10 and transplant reject?
 L14 0 L10 AND TRANSPLANT REJECT?
 => s l1 and transplant reject?
 L15 9 L1 AND TRANSPLANT REJECT?
 => d 1-9 115
 L15 ANSWER 1 OF 9 CARFLUS COPYRIGHT 2002 ACS
 1997-290112 CAPTUS
 DN 126-263167
 T Recombinant anti-CD4 antibodies for human therapy
 IN Hanna, Nabil; Newman, Roland A.; Reff, Mitchell E.
 PA Idec Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 154 pp.
 CODEN: PIXD2
 DT PATENT
 DR PATENT
 LA English
 FA.N.CNT 4
 PATENT NO.----- KIND DATE----- APPLICATION NO. DATE-----
 PI WO 9709351 A1 19970313 WO 1996-US14324 19960905
 W: AL, AM, AT, AU, AZ, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK,
 EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR,
 LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 RM: KE, LS, MR, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA
 US 6136310 A 200001024 US 1995-523894 19950906
 AU 9669162 A1 19970327 AU 1996-69162 19960905
 AU 717674 B2 20000330
 EP 834885 A1 19980729 EP 1996-929936 19960905
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 BR 9610404 A 19990706 BR 1996-10404 19960905
 JP 11514216 T2 1999107 JP 1996-511411 19960905
 NO 9000915 A 19980506 NO 1998-915 19980303
 PRAI US 1995-523894 A 19950906

L15 ANSWER 2 OF 9 USPATFULL
 2002-8551 USPATFULL
 IN POLYDITHIOCARBAMATE-CONTAINING NON-TARGETING MACROMOLECULES AND THE USE
 THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
 IN LAI, CHING-SAN, ENCINITAS, CA, UNITED STATES
 PI US 2002-05573 A1 20020418
 AI US 1999-409645 A1 1991001 (9)
 RLI Continuation-in-part of Ser. No. US 1997-899087, filed on 23 Jul 1997,
 PRRI US 1996-25867P 19960910 (60)
 DT Utility
 FS APPLICATION
 INLN.CNT 1763
 INCL INCLM: 514/006,000
 INCL INCL: 514/004,000; 514/054,000; 514/476,000; 514/483,000; 530/403,000;
 NCL NCIM: 514/006,000
 NCL: 514/044,000; 514/054,000; 514/476,000; 514/483,000; 530/403,000;
 IC [7] ICM: A61K031-415; C07H021-00; A61K031-715; A01N043-04; A61K031-70;
 ICS: A61K031-415; C07H021-00; A61K031-715; A01N043-04; A61K031-70;
 C07H001-00; C08H001-00; C07K017-00; A01N043-56; A61K031-27; A01N047-10
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L15 ANSWER 3 OF 9 USPATFULL
 AN 2001-202682 USPATFULL
 TI Therapeutic methods employing disulfide derivatives of dithiocarbonates
 and compositions useful therefor
 IN Iai, Ching-San, Encinitas, CA, United States
 Vassilev, Vassil, San Diego, CA, United States
 PA Medinov, Inc., San Diego, CA, United States (U.S. corporation)
 PI US 6316502 B1 2001113
 AI US 2000-065666 20000505 (9)
 RLI Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, now patented,
 Pat. No. US 6093743
 DT Utility
 FS GRANTED
 INLN.CNT 2591
 INCL INCLM: 514/599,000
 INCL INCL: 514/707,000; 514/825,000; 514/838,000; 514/831,000; 514/861,000;
 NCL NCIM: 514/866,000; 514/885,000; 514/903,000; 514/912,000; 514/925,000
 NCL: 514/599,000
 NCIM: 514/707,000; 514/825,000; 514/838,000; 514/831,000; 514/861,000;
 NCIM: 514/866,000; 514/885,000; 514/903,000; 514/912,000; 514/925,000
 IC [7] ICM: A01N037-18
 BXF 514/599; 514/707; 514/825; 514/838; 514/831; 514/861; 514/863; 514/885;
 514/866; 514/903; 514/912; 514/925
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L15 ANSWER 4 OF 9 USPATFULL
 AN 2001-173390 USPATFULL
 TI Transgenic non-human animals for producing heterologous antibodies
 IN Lonneberg, Nils, Redwood City, CA, United States
 PA Key, Robert M., San Francisco, CA, United States
 Genpharm International, Palo Alto, CA, United States (U.S. corporation)

PI US 6300129 B1 20011009
AI US 1996-738417 19961202 (8)
RJL Continuation-in-part of Ser. No. US 1996-728463, filed on 10 Oct 1996
Continuation-in-part of Ser. No. US 1995-54404, filed on 10 Oct 1995
now patented, Pat. No. US 5770429 Continuation-in-part of Ser. No. US
1994-352322, filed on 7 Dec 1994, now patented, Pat. No. US 5625126
Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994,
now abandoned Continuation-in-part of Ser. No. US 1993-165699, filed on
10 Dec 1993, now abandoned Continuation-in-part of Ser. No. US
1993-33131, filed on 3 Dec 1993, now abandoned Continuation-in-part of
Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned
Continuation-in-part of Ser. No. US 1993-96762, filed on 22 Jul 1993,
now patented, Pat. No. US 5814318 Continuation-in-part of Ser. No. US
1993-161739, filed on 3 Dec 1993, now abandoned Continuation-in-part of
1994-352322, filed on 7 Dec 1994, now patented, Pat. No. US 5625126
Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994,
now abandoned Continuation-in-part of Ser. No. US 1993-165699, filed on
10 Dec 1993, now abandoned Continuation-in-part of Ser. No. US
1993-161739, filed on 3 Dec 1993, now abandoned Continuation-in-part of
Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned
Continuation-in-part of Ser. No. US 1993-96762, filed on 22 Jul 1993,
now patented, Pat. No. US 5814318 Continuation-in-part of Ser. No. US
1993-33131, filed on 26 Jun 1993, now patented, Pat. No. US
589650 Continuation-in-part of Ser. No. US 1991-810219, filed on 17 Dec
1991, now patented, Pat. No. US 5669825 Continuation-in-part of Ser. No.
US 1990-575962, filed on 31 Aug 1990, now abandoned Continuation-in-part
of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned
DR Utility
FS GRANTED
LN.CNT 10030
INC1M: 435/326.000
INC1S: 435/346.000; 435/354.000; 530/387.100; 800/003.000; 800/006.000;
INC2M: 435/326.000
INC2S: 435/346.000; 435/354.000; 530/387.100; 800/003.000; 800/006.000;
INC3M: 435/326.000
INC3S: 435/346.000; 435/354.000; 530/387.100; 800/003.000; 800/006.000;
IC [7]
ICM: C12N015-86
IC5: C07K016-00; C12P021-00
EXK 800/3; 800/6; 800/18; 435/326; 435/346; 435/354; 530/387.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L15 ANSWER 5 OF 9 USPATFULL
AN 2001:1131342 USPATFULL
AT Conjugates of dithiocarbamate disulfides with pharmacologically active
agents and uses therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassiliev, Vassil P., San Diego, CA, United States
Wang, Tingmin, San Marcos, CA, United States
PA Medina, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6276627 B1 20010814
AI US 1998-416619 19991012 (9)
DT Utility
FS GRANTED
LN.CNT 2173
INC1M: 514/599.000
INC1S: 514/706.000; 514/707.000
INC2M: 514/599.000
INC2S: 514/706.000; 514/707.000
INC3M: 514/599.000
INC3S: 514/706.000; 514/707.000
IC [7]
ICM: A61K031-16
IC5: A61K031-05S; A61K031-105
EXK 514/599; 514/706; 514/707
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L15 ANSWER 6 OF 9 USPATFULL
AN 2001:102968 USPATFULL
IN High affinity human antibodies and human antibodies against digoxin
Lonberg, Nils, Woodside, CA, United States

PA Kay, Robert M., San Francisco, CA, United States (U.S. corporation)
PI GenPharm International, San Jose, CA, United States (U.S. corporation)
AI US 6255458 B1 20010703
RJL US 1998-22353 19980313 (9)
Continuation-in-part of Ser. No. US 1996-758417, filed on 2 Dec 1996
Continuation-in-part of Ser. No. US 1996-758463, filed on 10 Oct 1996
Continuation-in-part of Ser. No. US 1995-541404, filed on 10 Oct 1995,
now patented, Pat. No. US 5770429 Continuation-in-part of Ser. No. US
1994-352322, filed on 7 Dec 1994, now patented, Pat. No. US 5625126
Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994,
now abandoned Continuation-in-part of Ser. No. US 1993-165699, filed on
10 Dec 1993, now abandoned Continuation-in-part of Ser. No. US
1993-161739, filed on 3 Dec 1993, now abandoned Continuation-in-part of
Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned
Continuation-in-part of Ser. No. US 1993-96762, filed on 22 Jul 1993,
now abandoned Continuation-in-part of Ser. No. US 1993-165699, filed on
10 Dec 1993, now abandoned Continuation-in-part of Ser. No. US
1993-161739, filed on 3 Dec 1993, now abandoned Continuation-in-part of
Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned
Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994,
now abandoned Continuation-in-part of Ser. No. US 1993-165699, filed on
10 Dec 1993, now abandoned Continuation-in-part of Ser. No. US
1993-161739, filed on 3 Dec 1993, now abandoned Continuation-in-part of
Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned
Continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992, now patented, Pat. No. US
578960 Continuation-in-part of Ser. No. US 1992-834536, filed on 5 Feb
1992, now patented, Pat. No. US 5633425 Continuation-in-part of Ser. No.
US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5669825
Continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned
DT Utility
FS GRANTED
LN.CNT 10059
INC1M: 530/388.150
INC1S: 530/388.900; 435/326.000
INC2M: 530/388.150
INC2S: 435/326.000; 530/388.900
IC [7]
ICM: C07K016-00
EXK 424/15.1; 435/326; 435/346; 435/345; 530/388.9; 530/388.15
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L15 ANSWER 7 OF 9 USPATFULL
AN 2000:141878 USPATFULL
TI Recombinant anti-CD4 antibodies for human therapy
IN Hanna, Nabil, Oliventain, CA, United States
Newman, Roland Anthony, San Diego, CA, United States
Reff, Mitchell Elliott, San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 6136310 20001024
AI US 1995-523894 19950906 (8)
RJL Continuation-in-part of Ser. No. US 1995-476237, filed on 7 Jun 1995,
now patented, Pat. No. US 5756096 which is a continuation-in-part of
Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US
5655750 which is a continuation of Ser. No. US 1992-912292, filed on 10
Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US
1992-856281, filed on 23 Mar 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991,
now abandoned
DT Utility
FS Granted
LN.CNT 3398
INC1M: 424/154.100
INC1S: 530/387.300; 424/133.100; 424/141.100
INC2M: 424/154.100
INC2S: 424/133.100; 424/141.100; 530/387.300

IC [7] {7} ICM: A61K039-395

ICM: A61K039-395
IC: C12P021-08
EXP 530/387. 3: 424/133. 1; 424/141. 1; 424/54. 1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 9 USPATFULL

2000:95042 USPATFULL

TI Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
In Iai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
PA Medinox Inc., San Diego, CA, United States (U.S. corporation)
PI US 6093743 20000725
AT US 1998-103639 19980623 (9)

DT Utility

FS Granted

LN CNT 2691

INCL INCLM: 514/599. 000; 514/707. 000; 514/851. 000; 514/861. 000; 514/863. 000; 514/866. 000; 514/909. 000; 514/912. 000

NCL NCLM: 514/599. 000; 514/706. 000; 514/707. 000; 514/851. 000; 514/861. 000; 514/863. 000; 514/866. 000; 514/909. 000; 514/912. 000

IC [7] ICM: A61K031-16; A61K031-105

ICS: A61K031-095; A61K031-105

EXF 514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909; 514/912

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 9 OF 9 USPATFULL

AN 2000:1981 USPATFULL

TI Gamma-1 anti-human

IN Reff, Mitchell E., San Diego, CA, United States

Klotzter, William S., Carlsbad, CA, United States

Nakamura, Takehiko, Hiyashiyamato, Japan

PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)

Seikagaku Corporation, Japan (non-U.S. corporation)

PI US 6011138 20000104

AT US 1997-803085 19970220 (8)

DT Utility

FS Granted

LN CNT 2519

INCL INCLM: 530/388. 220

INCLS: 530/387. 300; 530/388. 200; 530/388. 150; 530/388. 730; 530/389. 600; 530/387. 900; 424/133. 100; 424/139. 100; 424/142. 100; 424/144. 100; 424/153. 100; 424/173. 100; 424/172. 100; 435/007. 240; 435/069. 600; 435/069. 000; 435/070. 210; 435/328. 000; 435/331. 000; 435/332. 000; 435/334. 000; 435/335. 000; 435/336. 000; 435/337. 000; 435/338. 000; 435/339. 000; 435/340. 000; 435/341. 000; 435/342. 000; 435/343. 000; 435/344. 000; 435/345. 000; 435/346. 000; 435/347. 000; 435/348. 000; 435/349. 000; 435/350. 000; 435/351. 000; 435/352. 000; 435/353. 000; 435/354. 000; 435/355. 000; 435/356. 000; 435/357. 000; 435/358. 000; 435/359. 000; 435/360. 000; 435/361. 000; 435/362. 000; 435/363. 000; 435/364. 000; 435/365. 000; 435/366. 000; 435/367. 000; 435/368. 000; 435/369. 000; 435/370. 000; 435/371. 000; 435/372. 000; 435/373. 000; 435/374. 000; 435/375. 000; 435/376. 000; 435/377. 000; 435/378. 000; 435/379. 000; 435/380. 000; 435/381. 000; 435/382. 000; 435/383. 000; 435/384. 000; 435/385. 000; 435/386. 000; 435/387. 000; 435/388. 000; 435/389. 000; 435/390. 000; 435/391. 000; 435/392. 000; 435/393. 000; 435/394. 000; 435/395. 000; 435/396. 000; 435/397. 000; 435/398. 000; 435/399. 000; 435/387. 14; 530/387. 3; 530/388. 22; 530/389. 6; 424/643. 1; 424/133. 1; 424/144. 1; 424/153. 1; 435/69. 6; 435/69. 7; 435/328; 435/334; 435/172. 3; 435/7. 24; 435/70. 21; 435/331; 435/343. 1

IC [6] ICM: A61K039-395

ICS: C12N005-12; C12N005-22; C07K016-28

EXP 530/387. 14; 530/387. 3; 530/388. 22; 530/389. 6; 424/643. 1;

424/133. 1; 424/144. 1; 424/153. 1;

435/69. 6; 435/69. 7; 435/328; 435/334; 435/172. 3; 435/7. 24; 435/70. 21;

435/331; 435/343. 1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 11 and transplant reject? his
=? TRUNCATION SYMBOL NOT VALID WITHIN 'REJECT?'
The truncation symbol ? may be used only at the end of a search term. To specify a variable character within a word use '' e.g., 'woman' to search for both 'woman' and 'women'. Enter "HELP" TRUNCATION" at an arrow prompt (=>) for more information.

=> d his

(FILE 'HOME' ENTERED AT 12:17:32 ON 25 JUN 2002)

FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT 12:18:32 ON 25 JUN 2002

L1 63 S CE9. 1
L2 0 S LI NOT PY=>1991
L3 39370 S CHIMER? AND ANTIBOD?
L4 5562 S PRIMATE AND HUMAN AND L3
L5 1188 S CD4 AND L4
L6 4708 S L3 AND CD4
L7 121 S L6 NOT PY=>1991
L8 62 DUP REM L7 (59 DUPLICATES REMOVED)
L9 3420 S TREAT? AND L6
L10 44 S L9 NOT PY=>1991
L11 0 S L10 AND GAMMA 4
L12 0 S L10 AND CESGAMMA4PE
L13 0 S CESGAMMA4PE
L14 0 S L10 AND TRANSPLANT REJECT?
L15 9 S LI AND TRANSPLANT REJECT?

FILE 'MEDLINE' ENTERED AT 12:18:32 ON 25 JUN 2002

FILE 'CANCERLIT' ENTERED AT 12:18:32 ON 25 JUN 2002

FILE 'EMBASE' ENTERED AT 12:18:32 ON 25 JUN 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:18:32 ON 25 JUN 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'USPAFULL' ENTERED AT 12:18:32 ON 25 JUN 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s ce9.1

L1 63 CE9.1

=> s 11 not PY=>1991

L2 4 FILES SEARCHED...

L2 0 LI NOT PY=>1991

=> s chimer? and antibody?

L3 39370 CHIMER? AND ANTIBOD?

=> s primate and human and 13

L4 5562 PRIMATE AND HUMAN AND L3

=> s cd4 and 14

L5 1188 CD4 AND L4

=> s 13 and cd4

L6 4 FILES SEARCHED...

L6 4708 L3 AND CD4

=> s 16 not PY=>1991

L7 4 FILES SEARCHED...

L7 121 L6 NOT PY=>1991

=> dup rem 17

L8 PROCESSING COMPLETED FOR L7 (59 DUPLICATES REMOVED)

=> d his

(FILE 'HOME' ENTERED AT 12:17:32 ON 25 JUN 2002)

FILE 'MEDLINE', 'CANCERLIT', 'EMBASE', 'BIOSIS', 'CAPLUS', 'USPAFULL', ENTERED AT 12:18:32 ON 25 JUN 2002

L1 63 S CE9.1

L1 0 LI NOT PY=>1991

L3 39370 S CHIMER? AND ANTIBOD?

L4 5562 S PRIMATE AND HUMAN AND L3

L5 1188 S CD4 AND L4

L6 4708 S L3 AND CD4

L7 121 S L6 NOT PY=>1991

L8 62 DUP REM L7 (59 DUPLICATES REMOVED)

=> d 11 1-63

L1 ANSWER 1 OF 63 MEDLINE

AN 2001465229 MEDLINE

DN 21401548 PubMed ID: 11510804

TI The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma.

AU Kon O M; Sinha B S; Loh L C; Barkans J; Compton C H; Barnes N C; Larche M; Kay A B

CS Department of Allergy and Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, London, UK.

SO EUROPEAN RESPIRATORY JOURNAL, (2001 Jul) 18 (1) 45-52.

CY Denmark (CLINICAL TRIAL)

DT Journal; Article; (JOURNAL ARTICLE)

(RANDOMIZED CONTROLLED TRIAL)

LA English

FS Priority Journals

ED 200201

Entered STN: 20010821

Last Updated on STN: 20020124

Entered Medline: 20020102

L1 ANSWER 2 OF 63 MEDLINE

AN 199924090 MEDLINE

DN 99294090 PubMed ID: 10367670

TI Flow cytometry in the preclinical development of biopharmaceuticals.

AU Gossett K A; Narayanan P K; Williams D M; Gore E R; Herzyk D J; Hart T K; Sellers T S

CS SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA. kent.gossett@sphsrh.com

SO TOXICOLOGIC PATHOLOGY, (1999 Jan-Feb) 27 (1) 32-7. Ref: 8

TI Journal code: 7905907. ISSN: 0192-6233.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LA English

FS Priority Journals

EM 199907

Entered STN: 19990806

ED

Last Updated on STN: 19990806

Entered Medline: 19990729

L1 ANSWER 3 OF 63 MEDLINE

AN 1999014931 MEDLINE

DN 99012931 PubMed ID: 9798587

TI Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma.

AU Kon O M; Sinha B S; Compton C H; Leonard T B; Kay A B; Barnes N C

CS London Chest Hospital, UK.

SO LANCET, (1998 Oct 3) 352 (9134) 1109-13.

TI Journal code: 2985213R. ISSN: 0140-6736.

CY ENGLAND: United Kingdom

DT (CLINICAL TRIAL)

Journal; Article; (JOURNAL ARTICLE)

(RANDOMIZED CONTROLLED TRIAL)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199811

ED Entered STN: 19990106

Last Updated on STN: 19990106

Entered Medline: 19981117

L1 ANSWER 4 OF 63 MEDLINE

AN 199833375 MEDLINE